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A novel fibrotic syndrome was recently reported in a South African family, 
characterised by poikiloderma, tendon contracture and progressive pulmonary 
fibrosis.  The pathological hallmark of this autosomal dominant condition is 
abnormal fibrosis of the skin, tendons and viscera, with variable penetrance.  
A candidate gene approach was adopted to investigate the molecular basis of 
this disease.  The TGFB1 gene, encoding the multifunctional cytokine 
Transforming Growth Factor-β1, as well components of the Smad signalling 
cascade (Smads -2, -3 and -7) were selected as candidates, based on their 
established role in fibrotic pathology. 
 
The length, sequence and expression of the TGFB1 transcript were examined 
in an affected and an unaffected family member, in order to identify possible 
disease-causing aberrations.  Additionally, expression and phosphorylation of 
the receptor-regulated Smads -2 and -3 were determined in skin fibroblasts 
from these family members, and two age- and sex-matched controls.  Finally, 
mRNA expression levels of SMAD7, encoding the inhibitory Smad7, were 
compared between the affected and unaffected individuals. 
 
Aside from two single nucleotide polymorphisms identified in the sequence of 
the TGFB1 transcript (neither of which appeared to be disease-causing), no 
differences in length or sequence were identified between the two family 
members.  Additionally, no significant difference in gene expression was 
observed (p=0.43).  In response to TGF-β1 treatment, no significant 
difference in Smad2/3 expression or phosphorylation was observed between 
individuals.  Similarly, the comparison between basal and TGF-β1-inducible 
SMAD7 expression revealed no significant difference between individuals 
(p=0.22 and p=0.88, respectively). 
 
These results indicate that the TGF-β1/Smad pathway is neither constitutively 
active nor hyperresponsive in affected individuals, and hence that the 
disease-causing defect responsible for the novel syndrome is unlikely to be 















2.1.1 Symptoms and Characterisation 
A novel familial fibrosing syndrome, affecting two generations of a South 
African family, was reported in the British Journal of Dermatology (Khumalo et 
al. 2006).  Major clinical manifestations of the disease include poikiloderma, 
tendon contracture, progressive pulmonary fibrosis, and degenerative 
changes in other organs (Fig. 1) (Khumalo et al. 2006).  The proband, a 
twenty-six year old woman (II.5), was found to have sparse hair and 
hypohydrosis (indicative of ectodermal dysplasia), sclerosis of the digits, and 
restricted lung function. She also displayed skin abnormalities including 
mottled pigmentation, telangiectasia, and epidermal atrophy – collectively 
described as poikiloderma – and reported a history of tendon contractures 
(Khumalo et al. 2006). 
 
Her father (I.2) and older brother (II.3), also afflicted with the disease, had 
shown similar skeletal and skin abnormalities, and had both died as a result of 
pulmonary fibrosis.  The latter presented with tendon contractures at a young 
age, requiring tendon lengthening surgery by the age of five years.  Upon 
postmortem examination, he was found to have tapered limbs, clubbing of 
fingers and toes, excessive fatty deposition in the abdominal region (including 
fatty infiltration of the pancreas and peripheral skeletal muscle) and elastic 
tissue degeneration, accompanied by calcification of the arteries (Khumalo et 
al. 2006). 
 
Symptoms involving the skin appear to be the most common, affecting both a 
half sister (II.2), from the father’s first marriage, and another brother (II.4), 
aged 31, who also exhibited limb abnormalities, hypertension, and left 
ventricular hypertrophy.  In all cases, autoimmune serology was negative 
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Figure 1. Pedigree of a South African family with a novel familial fibrotic syndrome.  The 
presence of affected individuals in both generations and of both sexes is indicative of 
autosomal dominant inheritance (Khumalo et al. 2006).  Individuals for whom biological 
material is available are indicated by additional coding (RTSAD1.1 – 1.4) and phenotypic 
abnormalities are listed where known. Males are indicated by a square and females by a 
circle.  Black symbols represent affected individuals and clear symbols, unaffected 
individuals.  A line drawn through a symbol indicates that the individual is deceased. 
 
Despite the observed clinical heterogeneity, many of the symptoms (including 
skin pathology, hypohydrosis and tendon contractures) are believed to be 
secondary to excessive fibrosis in the relevant tissues, an observation that is 
validated by histological findings (Khumalo et al. 2006). 
 
The mode of inheritance is likely to be autosomal dominant, since offspring of 
both sexes, and from both of the father’s marriages, show symptoms of the 
disease (Fig. 1). Transmission of the disease from the affected father to his 











presence of affected individuals in two generations of this small family is 
suggestive of a highly penetrant, dominant condition.  Neither of the 
marriages was consanguineous, and the two wives are unrelated, further 
supporting this assertion (Khumalo et al. 2006). 
 
2.1.2 Comparison and Contrast with Related Diseases 
Khumalo et al. (2006) suggested that the novel syndrome be classified as a 
member of the “hereditary sclerosing poikiloderma” group of diseases, which 
includes the premature aging disorders Rothmund-Thomson Syndrome (RTS) 
and Werner Syndrome, as well as the sclerosing poikiloderma of Weary.   
While the syndrome under study shares certain cutaneous manifestations with 
this family of diseases, and with the autoimmune disease scleroderma 
(systemic sclerosis), notable differences have led to its recognition as a novel 
disorder (Khumalo et al. 2006).  
 
2.1.2.1 Rothmund-Thomson Syndrome 
RTS, a rare syndrome characterised by a blistering rash, dermal atrophy, 
sparse hair and skeletal abnormalities, begins in early life as an acute-phase 
erythema of the cheeks, spreading eventually to the forehead, buttocks and 
extremities (Pesce and Rothe 1996; Wang et al. 2001).  This is followed by 
the chronic, or poikilodermatous phase, identified by the presence of 
“reticulated pigmentation, telangiectasiae, and areas of punctate dermal 
atrophy” (Wang et al. 2001), which persists into adulthood.  Additional 
symptoms include alopecia (affecting both scalp and facial hair), small stature, 
nail dystrophy, and a range of related skeletal and ocular abnormalities, 
including diminished or absent appendages (Kitao et al. 1999; Lindor et al. 
2000; Pesce and Rothe 1996).  
 
RTS is caused by the RECQL4 gene, situated on chromosome 8q24.3. 
RECQL4 is a member of the RecQ-like helicase family, which is hypothesized 
to play a “guardian” role within eukaryotic cells, maintaining genomic stability 
(Kitao et al. 1999; Lindor et al. 2000).  Defects in RECQL4, leading to RTS, 












2.1.2.2 Werner Syndrome 
Werner Syndrome, which is, like RTS, an autosomal recessive premature 
aging disorder, differs from other disorders in this category by virtue of a later 
age of onset (usually in either the third or fourth decade).  Symptoms typically 
include short stature, thin, spindly limbs coupled with a stocky trunk, 
scleroderma-like changes to skin, epidermal atrophy, telangiectasia, mottled 
pigmentation, and alopecia affecting both facial and body hair.  
Musculoskeletal symptoms, such as osteoporosis, sclerodactyly and 
calcification of ligaments and tendons, as well as cardiovascular 
manifestations (namely valvular calcification and cardiac hypertrophy and 
fibrosis) have also been observed (Pesce and Rothe 1996).  Werner 
Syndrome is caused by mutations in the RECQ3 gene, another member of 
the human RecQ helicase family (Lindor et al. 2000). 
 
2.1.2.3 Weary Sclerosing Poikiloderma 
The hereditary sclerosing poikiloderma first described by Weary and 
colleagues in 1969 is distinguished by the presence of five clinical features, 
namely: generalized poikiloderma, sclerosis of the hands and feet, 
hyperkeratotic and sclerotic bands in the armpits and other regions, finger 
clubbing, and tissue calcification (Weary et al. 1969).  These findings were 
corroborated by Grau Salvat et al. (1999), who also observed calcification of 
the aorta and mitral valves in their case study.   
 
2.1.2.4 Scleroderma/Systemic Sclerosis 
Aspects of the novel syndrome have also been likened to scleroderma 
(systemic sclerosis), a chronic systemic autoimmune disease of unknown 
cause, whose symptoms include vascular dysfunction, the production of 
autoantibodies, and excessive deposition of extracellular matrix (ECM) 
components, ultimately leading to progressive fibrosis of the skin, lungs and 
other organs (Dong et al. 2002; Saito et al. 2002).  Telangiectasiae, loss of 
sweat glands, and periarticular calcinosis have also been observed (Jimenez 













2.1.2.5 Contrast with Novel Disease 
While certain of these symptoms, particularly those involving the skin, and to 
a lesser degree, the limbs, can be identified in the South African family 
described by Khumalo et al. (2006), notable differences exist. For instance, 
two of the prominent features of the recently characterised syndrome, 
pulmonary fibrosis and tendon contractures, are not recognized as symptoms 
of the hereditary poikilodermas. Additionally, Rothmund-Thomson and Werner 
Syndromes are inherited in an autosomal recessive fashion, and thus do not 
fit the profile of the novel disease (Khumalo et al. 2006; Wang et al. 2001).   
 
Affected members of the newly described family show no evidence of 
cutaneous fibrous bands or valvular heart disease (characteristic of Weary 
sclerosing poikiloderma), or of cataracts or hypogonadism (symptoms of RTS) 
(Khumalo et al. 2006).  They are also autoimmune negative, ruling out 
systemic sclerosis as a possible cause, despite previously reported 
associations between pulmonary fibrosis (a prominent symptom of the novel 
disorder) and systemic sclerosis (Steen 2005; White 2003).    
 
2.2 Methods of Finding Determinant Gene  
The identification of gene(s) and/or protein(s) responsible for the observed 
phenotype represents an important first step in the molecular characterisation 
of a novel syndrome.  The genes responsible for Rothmund-Thomson and 
Werner Syndromes (RECQL4 and RECQ3, respectively), were deemed to be 
unlikely candidates, because of the discrepancies in symptoms and mode of 
inheritance observed between these disorders and the novel disease 
described by Khumalo et al. (2006).  The decision was therefore made to look 
for other genes or proteins, which may play a causal role in this disorder. 
Several methods are currently employed to prioritise genes for investigation, 
including linkage-based methods, such as linkage analysis, positional cloning 
and linkage disequilibrium mapping, the candidate gene approach, and 
genome-wide transcriptional profiling (McCarthy et al. 2003).  However, not all 
of these are readily applicable to small cohort sizes, such as the affected 











2.2.1 Linkage-Based Methods 
Linkage-based techniques for identifying disease-causing or -susceptibility 
genes are based on the assumption that chromosomal regions (defined by 
polymorphic markers) that contain the determinant gene will be likely to be 
conserved in individuals affected with the disease of interest, and that the 
frequency of such disease-associated allele(s) will be higher in the affected 
population than amongst unaffected individuals (Lander and Kruglyak 1995; 
McCarthy et al. 2003).  In practice, this amounts to a scan of the entire 
genome (or of a relevant chromosomal region previously identified) using a 
dense collection of Single Nucleotide Polymorphisms (SNPs) or microsatellite 
markers (e.g. dinucleotide repeats), calculation of an approximate linkage 
statistic at each position along the genome, and identification of regions at 
which the value for linkage greatly exceeds that which would be expected to 
occur by chance (Lander and Kruglyak 1995).   There are two common types 
of linkage-based methods, namely linkage analysis and linkage disequilibrium 
mapping. 
 
In linkage analysis, disease gene localisation is based on direct observation of 
recombination within families (McCarthy et al. 2003).  These studies focus on 
the investigation of chromosomal regions that are co-inherited with the 
disease in families (Kruglyak 1999).  Genes which are found to be present on 
conserved haplotypes (unaltered by meiotic recombination) in affected 
individuals after several rounds of linkage mapping may be screened for 
disease-causing mutations in a process known as positional cloning, which 
has proven highly successful in the identification of genes responsible for 
diseases with a simple Mendelian inheritance pattern (McCarthy et al. 2003). 
 
However, because of the often weak associations between multiple 
susceptibility genes and the observed phenotype, linkage analysis cannot be 
as readily applied to the problem of complex disorders (McCarthy et al. 2003; 
Terwilliger and Weiss 1998).  In such instances, Linkage Disequilibrium (LD) 
mapping has proved useful.  LD refers to the non-random assortment of 
alleles, and appears as a difference in allele frequency distribution of one 











chromosome (Terwilliger and Weiss 1998).  Thus, if a locus is hypothesised to 
have a disease-predisposing allele, and if this allele is in LD with alleles of a 
marker closely positioned on the same chromosome, the disease gene can be 
mapped. 
 
This process is of particular relevance to complex disorders, since the nature 
of a LD screen does not imply the presence of a single conserved haplotype 
surrounding the susceptibility gene, nor does it stipulate any particular mode 
of inheritance (Terwilliger and Weiss 1998).  Additionally, in allowing for 
multiple alleles of a particular marker locus, LD mapping is amenable to 
population-wide studies, rather than being restricted to single families at a 
time (Kruglyak 1999).  LD is also useful in the fine-mapping of a disease-
linked locus identified by linkage analysis, and as such may prove vital in 
refining the positional cloning approach and extending its applications to 
multifactorial diseases (Kruglyak 1999; McCarthy et al. 2003). 
 
As a result of the central role of statistical inference in these two techniques, 
however, sample size becomes a limiting factor in determining the 
significance of a result.  In linkage analysis, a logarithm of odds (LOD) score 
of 3 or greater is required to support a hypothesis of linkage in Mendelian 
traits, with complex traits demanding more stringent thresholds of 
significance.  The number of meioses from which a statistically sound 
inference can be drawn, as well as the values of linkage which should be 
considered significant, also remain contentious issues in LD studies (Lander 
and Kruglyak 1995).  Smaller sample sizes are generally acknowledged to be 
less informative, since their results are often indistinguishable from what may 
be expected purely by chance.  For this reason, linkage-based techniques 
cannot be used for small families (such as the pedigree for the novel 
syndrome under investigation), unless combined with other methods of 
determinant gene identification. 
 
It must however be noted that a “negative” linkage result obtained in a small 
family can be deemed conclusive.  The abolition of a conserved haplotype in 











suggest that genes within that chromosomal region are not linked to the 
disease phenotype.  In large kindreds, this is indicated by a LOD score of less 
than -2, while in smaller families, the evidence for meiotic recombination is 
based on direct observation, comparing markers present in individuals in two 
successive generations. This approach, known as “exclusion mapping” may 
be employed to rule out the involvement of certain genes or regions of the 
genome, particularly when inferences of causality cannot be made, or in 
cases when “positive” results should be treated with caution (Ott 1991).   
 
2.2.2 Genome-Wide Transcriptional Profiling            
With the advent of oligonucleotide array technology, it has become possible to 
examine differential gene expression in wildtype and diseased tissues on a 
larger scale.  This is particularly useful, as it enables the visualisation of 
several thousand genes at a time, and allows the examination of in vivo or in 
vitro consequences of the disease phenotype on gene expression levels.  
Additionally, genome-wide analyses not only provide clues to the biological 
candidacy of differentially expressed genes, but may also indicate possible 
disease-associated pathways (McCarthy et al. 2003). 
 
Despite the obvious advantages, there are major drawbacks to the use of 
such techniques, such as prohibitive costs and high margin for experimental 
error, which are exacerbated in the case of small cohorts or families.  
Additionally, the bias of transcriptional profiling towards detection of 
transcriptional, rather than translational or post-translational gene expression 
differences, may make genome-wide transcriptional profiling a less 
appropriate tool in certain contexts (McCarthy et al. 2003). 
 
2.2.3 Candidate Gene Approach   
 A third commonly used approach to finding the genetic determinants of 
disease is the candidate gene approach.  This technique is based on a 
correlation between known gene function and the known (or presumed) 
biological basis of the disease (McCarthy et al. 2003).  The aim is to identify 
genes with a high prior probability of involvement, and to prioritise these 











profiling or mutation screening.  Although less successful in the discovery of 
disease genes than linkage-based methods, the candidate locus approach is 
invaluable in situations in which a whole-genome linkage analysis experiment 
is inappropriate (McCarthy et al. 2003; Ott 1991). 
 
A significant downfall of this approach is that it relies on assumptions – firstly, 
that the gene function, and the consequence of mutations of the gene, are 
known and secondly, that the biological basis of the disease has been 
elucidated.  It is often the latter that provides more of an obstacle, since the 
biology of many diseases, particularly the complex and syndromic cases, 
remains elusive.  Nonetheless, the identification of possible candidate genes 
by this method may still be a valuable tool in guiding linkage analysis 
experiments, and other types of investigation (McCarthy et al. 2003; Ott 
1991). 
 
2.2.4 The Identification of a Determinant Gene in this Investigation 
Because of the small number of individuals available for study in this case – 
four family members, of whom three were affected, and one deceased – the 
candidate gene approach was employed, to identify a possible determinant 
gene.  Based on the prominence of fibrosis in the novel disorder, the TGFB1 
gene, encoding the profibrotic cytokine Transforming Growth Factor β1 (TGF-
β1), had previously been suggested as a potential candidate (Khumalo et al. 
2006).  Additional candidates were identified based on their role in the 
profibrotic signalling cascade initiated by TGF-β1 – these included the 
signalling proteins Smad2, Smad3, Smad4 and Smad7.   
 
2.3 The Case for the TGF-β1/Smad Signalling Pathway  
TGF-β1, the prototype of the TGF-β protein superfamily, is a ubiquitously 
expressed, multifunctional cytokine, whose cellular effects are mediated by 
Type I and II serine-threonine kinase receptors and the Smad family of 
signalling proteins (Blobe et al. 2000; Venkatesan et al. 2004).  The role of the 











synthesis, and hence in the development of fibrosis has been well 
characterised (Arany et al. 2006; Clouthier et al. 1997).    
 
2.3.1 Structure of TGF-β1 Gene and Protein   
The TGFB1 gene is situated on chromosome 19q13, and comprises 7 exons, 
large introns and 5’ and 3’ untranslated regions (Awad et al. 1998; Blobe et al. 
2000; Kim et al. 1989; Shah et al. 2006).  Transcription is regulated by two 
major transcription start sites, with regulatory regions extending up to 2.7 
kilobases upstream of the translation start codon, as determined by Kim et al. 
(1989) and Shah et al. (2006).  These include putative binding sites for the 
transcription factors Stimulatory Protein 1 (Sp1) and Nuclear Factor, as well 
as several distal enhancers and repressors (Kim et al. 1989; Shah et al. 
2006). 
The C-terminal region of the protein encodes mature TGF-β1, while the N-
terminal domain comprises the signal sequence (which targets the 
polypeptide to the Endoplasmic Reticulum (ER) and Golgi apparatus for 
processing), and the Latency Associated Peptide (LAP) (Munger et al. 1999) 
(Fig. 2).  TGF-β1 is synthesised as a preproprotein, which undergoes 
extensive modification in the Golgi apparatus, including signal peptide 
cleavage, glycosylation and dimerisation by means of disulphide bonds 
(Janssens et al. 2000), to form a homodimer of approximately 75kDa (Annes 
et al. 2003).   After dimerisation, the LAP is cleaved from proTGF-β1 in the 
Golgi by furin-type enzymes (yielding a 25kDa protein product), but remains 
non-covalently bound, rendering TGF-β1 inactive and incapable of binding to 
its receptors (Annes et al. 2003; Janssens et al. 2000; Munger et al. 1999).  
Association with the Latent TGF-β Binding Protein (LTBP) completes the 
latent TGF-β1 complex (Fig. 2), and allows it to become covalently associated 
with the ECM, following secretion (Annes et al. 2003).  Under normal 
conditions, most secreted TGF-β1 can be found in this form (Tesseur et al. 













Figure 2. Structure and processing of TGF-β1 prepropeptide.  The preprocytokine, 
comprising signal peptide, Latency Associated Peptide (LAP) and Mature TGF-β1 is directed 
into the Golgi for modification, at which point the signal peptide is cleaved by signal 
peptidase.  Following dimerisation, the LAP is cleaved from mature TGF-β1, but remains non-
covalently associated during secretion and binding to the ECM.  Latent TGF-β1 Binding 
Protein (LTBP) binds to this complex and retains TGF-β1 in an inactive form until 
environmental stimuli trigger its release.  
The mechanisms underlying TGF-β1 activation (that is, the liberation of TGF-
β1 from its latent complex) are not fully understood (Annes et al. 2003; 
Janssens et al. 2000).  However, acid activation (in vitro) and proteolytic 
cleavage (in vivo) have been demonstrated (Munger et al. 1999).  Annes et al. 
(2003) propose a paradigm in which latent TGF-β1 is considered a sensor of 
the extracellular environment, with the LTBP acting as the localiser (by 
facilitating binding to the ECM), the LAP functioning as the sensor 
(responding to activators by releasing TGF-β1), and TGF-β1 playing the role 
of the effector, bringing about downstream effects. 











2.3.2 Structure of Smad Family Proteins 
The Smad family consists of ten proteins which are involved in TGF-β 
superfamily signalling pathways (Arai et al. 1998 Blobe et al. 2000).  So-called 
because of their homology to Drosophila Mad (Mothers Against 
Decapentaplegic) and C. elegans Sma proteins, human Smads may be 
divided into TGF-β-responsive (Smad2, -3, -4, -6 and -7), and Bone 
Morphogenic Protein (BMP)-responsive (Smad1, -4, -5 and -8) elements 
(Heldin et al. 1997; Lo et al. 1998; Massagué 1998; ten Dijke et al. 2000).  
 
Additionally, Smads are classified according to their function. Those which 
interact directly with, and are phosphorylated by, activated Type I 
Serine/Threonine Kinase Receptors are designated “Receptor Regulated-
Smads” (R-Smads), while those common to both pathways are referred to as 
“Common Partner Smads” (Co-Smads). Those which act to downregulate 
signalling, meanwhile, are known as Inhibitory Smads (I-Smads) (Massagué 
1998).  In the absence of signalling, R-Smads are localised predominantly in 
the cytoplasm, while Co-Smads are distributed equally between the cytoplasm 
and nucleus (Ross et al. 2007; van Laar et al. 2005).  In the case of TGF-β 
signalling, there are two receptor-interacting Smads (Smad2 and Smad3), a 
single Co-Smad (Smad4) and two inhibitory Smads (Smad6 and -7), the 
functions of which are discussed in more detail in 2.3.3 (Blobe et al. 2000). 
 
The generalised Smad protein structure, shared by the R-Smads and Smad4, 
consists of two Mad-Homology (MH) domains (the N-terminal MH1 and the C-
terminal MH2), which display a high degree of sequence similarity (pairwise 
sequence identity 40-94% for MH1, and 38-98% for MH2) and are separated 
by a variable, proline-rich linker region (Fig. 3) (Massagué 1998; Shi et al. 
1998).  The MH1 domain is responsible for DNA-binding.  In the case of the 
R-Smads and Co-Smads, this domain interacts directly with the promoters of 
target genes in the nucleus, regulating their transcription in response to TGF-
β signalling (Chacko et al. 2001; Lo et al. 1999).  This is accomplished via a 
novel DNA-binding motif, an 11-residue β-hairpin, which contacts DNA in a 
sequence-specific manner, in the major groove (Kloos et al. 2002; Shi et al. 











as a result of a 30-bp insertion within this N-terminal region and therefore 
relies on the DNA-binding abilities of heteromeric partners in order to effect its 
function (Ross et al. 2007; Shi 1998; Zawel 1998).  The MH1 domain also 
serves to inhibit functional activity of the MH2 domain, prior to receptor-
mediated phosphorylation, and contains a nuclear import/export signal, which 
aids in the transport of heteromeric R-Smad/Co-Smad complexes to and from 





Figure 3.  Generalised structure of the Smad protein family, showing representatives of the 
receptor-activated/receptor-regulated (Smad2 and 3), common-partner (Smad4), and 
inhibitory Smads (Smad7). MH1 and MH2 represent Mad homology regions 1 and 2, 
respectively.  The functions of these domains are listed below Smad4.  Phosphorylation sites 
for Erk/MAPK (Px[S/T]Ps) and type I TGF-β receptors (SxS) on Smad2 and -3 are indicated. 
Checkered boxes denote exons present in Smad2 but not Smad3. The β-hairpin DNA-binding 
domain (Smad2, -3 and -4) and L3 loop (Smad2 and -3) are also indicated.  The 
chromosomal location of each of the human Smads is shown on the right. 
 
The MH2 domain, on the other hand, is responsible for contact with receptors 
(in the case of R-Smads), homo- and heteromeric complex formation with 
other Smads and interactions with co-activator or co-repressor proteins (Lo et 
al. 1998; Lo et al. 1999; Massagué 1998; ten Dijke et al. 2000).  Crucial to the 
 











functions of this C-terminal domain are two highly conserved motifs – the L3 
loop, and the so-called “C-tail” (Lo et al. 1998; Massagué 1998). 
 
The first of these, the L3 loop, was identified by Lo and colleagues in 1998, as 
a 17-amino acid loop protruding from the β-sandwich core of the MH2 domain, 
in the R-Smads and Smad4 (Fig. 3).  The sequence of the loop is conserved 
among both the TGF-β-responsive and BMP-responsive Smads, but differs 
between the two groups at two amino acid positions.  Lo et al. demonstrated 
that by swopping these variant amino acids between groups, a difference in 
ligand sensitivity could be induced, leading to phosphorylation of Smad1 in 
response to TGF-β signalling and phosphorylation of Smad2 in response to 
BMP signalling in vitro.  They therefore concluded that the L3 loop was a 
crucial determinant of the specificity of Receptor/Smad interactions, and 
postulated that in the case of the non-receptor-interacting Smad4, the loop 
might function in heteromeric association with the R-Smads (Lo et al. 1998).   
 
The “C-tail” consists of a stretch of 11 amino acids at the extreme C-terminal 
of the R-Smads, which directly contacts Type I receptors during 
phosphorylation (Lo et al. 1998).  Two serine residues within a conserved 
sequence motif SS[V/M]S (also designated SSXS) contained in the “tail”, act 
as a substrate for phosphorylation by activated receptors and it is this 
phosphorylation which triggers R-Smad homo- and heteromerisation (through 
electrostatic interactions with L3 loops of neighbouring Smads) and nuclear 
translocation (Chacko et al. 2001; Massagué 1998; ten Dijke et al. 2000).  
Thus, the L3 loop and the C-tail together are responsible for R-Smad 
activation (Lo et al. 1998). 
 
The variable linker region, which joins the MH1 and MH2 domains, has been 
shown in R-Smads to be phosphorylated by Mitogen Activated Protein 
Kinases (MAP Kinases), resulting in inhibition of nuclear translocation (Lo et 
al. 1998; Lo et al. 1999; ten Dijke et al. 2000).  The integration of such signals 













Although the MH2 sequences of Smad4 and the R-Smads are highly similar in 
sequence, sharing 50% identity, Smad4 is distinguishable by a 35-amino acid 
insertion, which extends from the core (Chacko et al. 2001).  Smad4 also 
lacks the SSXS motif, and is therefore not phosphorylated by activated 
serine/threonine kinase receptors (Zhang et al. 1996). 
 
The structure of the I-Smads is markedly different, however, as a result of 
their distinct function in the Smad signalling cascade.  Although they share a 
similar MH2 domain to that of the other Smad types, these inhibitory proteins 
contain a more divergent N-terminal region, which lacks a DNA-binding 
domain (Ross et al. 2007; Takagawa et al. 2003).  As with the R-Smads, the 
MH2 domain mediates receptor binding.  However, in this case, the objective 
is not phosphorylation (I-Smads lack the SSXS motif), but the prevention of R-
Smad binding, in order to attenuate the signal (Nakao et al. 1997a; Ross et al. 
2007; Takagawa et al. 2003). 
 
2.3.3 TGF-β1/Smad Signalling  
Active TGF-β1 signals via a heterodimeric complex of type I and type II 
receptor serine/threonine kinases (TβRI and II).  Ligand binding to TβRII leads 
to recruitment and phosphorylation of TβRI, which in turn results in the 
phosphorylation of downstream targets in the Smad signal transduction 
pathway, propagating the profibrotic signal (Clouthier et al. 1997; Kavsak et 
al. 2000;  Nakao et al. 1997b; Zhang et al. 1996) (Fig. 4). 
 
Specifically, Smad2 and -3 (the TGF-β1-responsive R-Smads) have been 
shown to associate with the RI-RII complex via the C-terminal L3 loop, and to 
be phosphorylated by TβRI upon binding (Lo et al. 1998; Zhang et al. 1996).  
Phosphorylation occurs at the C-terminal SSXS motif (see 2.3.3), and results 
in a conformational change, releasing the Smad MH2 domains from inhibition 
by their MH1 domains (Hill 1999).  This conformational change also results in 
dissociation of the Smads from SARA (Smad Anchor for Receptor Activation), 
a FYVE-domain protein responsible for subcellular localisation of the R-
Smads in the cytoplasm, and for their recruitment to activated TGF-β 











                
 
 
Figure 4.  Proposed signalling of TGF-β1 via Smad proteins. TGF-β1 (Ligand) binding to 
TβRII leads to recruitment and phosphorylation of TβRI.  This results in phosphorylation of the 
receptor regulated Smads (2 and 3), causing a conformational change, and enabling them to 
bind to the co-Smad, Smad 4.  This heteromeric complex is translocated into the nucleus, 
where it activates transcription of fibrogenic genes. The inhibitory Smads (6 and 7) prevent 
binding of receptor-regulated Smads to the TβRI/II complex.  Smad 7 has also been shown to 
mediate ubiquitination of the TBRI/II complex. 
 
R-Smad release from SARA is accompanied by the concomitant formation of 
heterotrimers, consisting of two R-Smads and one molecule of Smad4.  MH2 
domain interactions act to stabilise the trimers, through the association of R-
Smad phosphorylated C-tails with the L3 loops of neighbouring subunits 
(Chacko et al. 2001).  Activated trimeric complexes then enter the nucleus to 
initiate transcriptional regulation of target genes, such as those involved in 
ECM production and wound repair (Arai et al. 1998; Chen et al. 2002; Mori et 
al. 2000; Nakao et al. 1997b; Tsukazaki et al. 1998; Zawel et al. 1998; Zhang 























            
         













Transcriptional activation is accomplished through the binding of R-Smad/Co-
Smad complexes to a conserved 4-bp binding site, 5’-GTCT-3’ (known as the 
Smad Binding Element or SBE), found in the promoters of TGF-β1 target 
genes, such as collagenase and collagen type VII.  DNA-binding MH1 
domains of the complexed Smads contact the SBE in a sequence-specific 
manner, via hydrogen bonds between MH1 amino acid side chains and DNA 
bases of this conserved recognition sequence (Johnson et al. 1999; Shi et al. 
1998; Zawel et al. 1998). 
 
However, the length of this sequence indicates that it is likely to be present in 
the promoters of many different genes, simply by chance.  The fact that the 
SBE is not restricted to TGF-β1-responsive genes suggests that a 
combinatorial approach is required for the specific regulation of target genes 
in response to TGF-β1 signalling (Shi et al. 1998). 
 
The ubiquitous, constitutive expression of the R-Smad and Co-Smad proteins 
also points to the importance of tissue- and cell-type specific regulatory 
transcription factors in determining the expression levels of TGF-β1 signalling 
targets (Mori et al. 2000).  In reviewing the role of Smad proteins in systemic 
sclerosis, Varga and colleagues suggest that “the specificity of Smad 
transcriptional responses is achieved, in part, through selective interaction 
with other regulatory proteins expressed in a cell-specific manner” (Varga et 
al. 2002). 
 
For instance, R-Smad/Co-Smad complexes may interact with the co-
activators CBP/p300 to exert their transcriptional effects (Janknecht et al. 
1998; Varga et al. 2002).  Interactions are commonly mediated by the Smad 
MH2 domain, and affinity for co-activators (or for co-repressors) is enhanced 
following phosphorylation by Type I receptors (Janknecht et al. 1998).  
 
Activation of the TGF-β1/Smad signalling pathway is tightly controlled. 
Inhibitory Smads, such as Smad6 and Smad7, negatively regulate TGF-β1 
signalling by interacting with activated TβRI (thereby inhibiting the binding of 











regulated Smads with Smad4 (Nakao et al. 1997a; Nakao et al. 2002).  This 
was demonstrated by Kavsak et al. (2000), who showed that Smad7 acts as 
an adaptor molecule, which recruits Smurf2, an E3 ubiquitin-protein ligase, to 
the TGF-β1 receptor complex, resulting in its degradation.   
 
Unlike the R- and Co-Smads, which are constitutively expressed even in the 
absence of signalling, the I-Smads are rapidly induced at the transcriptional 
level by activated Smad3/Smad4 heteromers (Nakao et al. 2002).  Elevated 
expression of these inhibitory components acts as a negative feedback loop, 
serving to attenuate signalling in normal tissues (Takagawa et al. 2003; Mori 
et al. 2000; Nakao et al. 1997a).  Autoregulation of signalling also occurs at 
the level of Smad3, which is downregulated at the mRNA and protein level, 
following prolonged TGF-β1 signalling (Mori et al. 2000; Varga et al. 2002).  In 
normal tissues, these regulatory mechanisms prevent constitutive signalling, 
which could lead to overexpression of target genes, and ultimately to disease.  
 
2.3.4 Physiological Role of the TGF-β/Smad Signalling Pathway in the 
Extracellular Matrix   
The TGF-β1/Smad signalling cascade plays a vital role in cell growth, 
differentiation and tissue repair, as well as in the stimulation and regulation of 
fibre synthesis in the ECM (Awad et al. 1998; Blobe et al. 2000).  In response 
to tissue injury, increased levels of TGF-β1 contribute to wound healing by 
promoting transcription of structural proteins (such as collagens), suppressing 
the production of matrix proteases, and increasing the levels of protease 
inhibitors, resulting in enhanced ECM deposition (Border and Noble 1994; 
Varga et al. 2002). 
 
2.3.5 Proposed Role of TGF-β1 in Disease 
Although the novel disease described by Khumalo et al. (2006) is clinically 
heterogeneous, the common factor underlying many of the observed 
symptoms appears to be widespread fibrosis (Khumalo et al. 2006).  The 
presence of fibrosis in disease is most often due to an imbalance in ECM 











This is equivalent to hyper-induction of the wound-repair pathway, in which 
TGF-β1 and its signalling cascade are normally involved (Border and Noble 
1994).  Thus, it follows that mutations in, or dysregulation of expression of the 
TGFB1 gene may be responsible for the pathogenesis of fibrosis, via 
upregulation of profibrotic target genes in the absence of a stimulus, 
effectively causing constitutive activation of the TGF-β1 pathway (Dong et al. 
2002). The ubiquitous nature of TGF-β1 expression may also provide an 
explanation for the systemic effects observed in affected individuals (Blobe et 
al. 2000; Varga et al. 2002). 
 
Links between TGF-β1 overexpression and fibrosis of the lungs, skin and 
other organs have been demonstrated by several research groups (reviewed 
by Bartram and Speer 2004 and Blobe et al. 2000). Broekelmann et al. (1991) 
demonstrated markedly elevated levels of TGF-β1 expression in areas of 
fibrosis in the lung, which were associated with an increase in the production 
of collagen. Based on their observations, they proposed a role for TGF-β1 in 
human pulmonary fibrosis (Broekelmann et al. 1991).  These results were 
supported by the histological findings of Khalil et al. (1996), who discovered 
increased TGF-β1 expression in epithelial cells of patients with chronic 
pulmonary fibrosis. 
 
By overexpressing the TGFB1 gene, coupled to the regulatory sequence of 
the phosphoenolpyruvate carboxykinase gene, Clouthier and colleagues 
generated a transgenic mouse model, with ectopic TGF-β1 expression 
localised to the liver, kidney, and white and brown adipose tissue (Clouthier et 
al. 1997).  In organs in which TGF-β1 was overexpressed, pathological 
accumulation of ECM components, resulting in severe fibrosis, was observed.  
Additionally, transgenic mice frequently showed a loss of skin elasticity, 
secondary to excessive fibre deposition in the underlying adipose tissue. 
These findings provided strong evidence to support the link between TGF-β1 
and fibrotic disease (Clouthier et al. 1997). 
 
In the tight-skin mouse model of systemic sclerosis, Zhu et al. (2005) 











fibroblasts, which they attributed to polymorphisms in the promoter of the 
TGFB1 gene.  This is not the first case in which the levels of TGF-β1 protein 
in the body have been shown to be under genetic control (Grainger et al. 
1999). Single nucleotide polymorphisms in the regulatory region of the gene, 
as well as in the signal peptide sequence, which regulates trafficking of TGF-
β1 through the Endoplasmic Reticulum (Crilly et al. 2002), have been found to 
correlate with increased secretion, and hence higher serum levels, of TGF-β1 
(Dunning et al. 2003; Shah et al. 2006). These include a T to C substitution at 
codon 10 (resulting in an amino acid change from Leucine to Proline), and a C 
to G (Proline to Arginine) change at codon 25 (Kim et al. 1989; Shah et al. 
2006). The presence of a Proline at position 10 has been found to be 
associated with an increased incidence of lung fibrosis (Awad et al. 1999), 
poorer prognosis in Idiopathic Pulmonary Fibrosis (Xaubet et al. 2003), and 
the development of scleroderma (Crilly et al. 2002), all of which are 
symptomatically associated with the novel disease.  Individuals homozygous 
for Arginine at position 25 have also been shown to have an increased 
susceptibility to pulmonary fibrosis (Awad et al. 1998). 
 
TGF-β1 was thus concluded to be a logical candidate for investigation, since 
its functions, and known roles in human pathology correspond to the 
proposed biological basis of the novel disease. 
 
2.3.6 Proposed Role of Smad Proteins in Disease 
The downstream components of the TGF-β1/Smad pathway and their role in 
human disease have also been well described (see Blobe et al. 2000; and 
Heldin et al. 1997 for reviews).  Similar to TGF-β1, aberrations leading to 
prolonged or constitutive signalling have been shown to result in upregulation 
of ECM target genes, leading ultimately to fibrotic disease (Varga et al. 2002).  
These aberrations include excessive phosphorylation and nuclear 
accumulation of R-Smads, failure to downregulate Smad3 following TGF-β1 
signalling, and decreased expression of inhibitory components of the 












In a bleomycin-induced murine model of scleroderma, Takagawa et al. (2003) 
demonstrated sustained induction of TGF-β/Smad signalling in dermal 
fibroblasts, which appeared to be associated with a relative deficiency in 
Smad7 protein expression. These findings were corroborated by Venkatesan 
et al. (2004), who showed that decreased levels of Smad7 protein were 
associated with increased phosphorylation and nuclear translocation of the 
transcriptional activator R-Smads, Smad2, -3 and -4, in the lung fibroblasts of 
bleomycin-treated rats.   
 
Dong and colleagues (2002) extended these experiments to human systemic 
sclerosis, demonstrating a decrease in both basal and TGF-β1-inducible 
levels of Smad7, in scleroderma lesions (in vivo) and cultured scleroderma 
fibroblasts (in vitro).  This selective decrease in expression of the inhibitory 
Smad was associated with an increase in TGF-β1 signalling events, most 
notably, increased phosphorylation of Smad2 and -3, and elevated 
transcription of the profibrotic target gene, plasminogen activator inhibitor 
type-1 (PAI-1).  Overexpression of endogenous Smad7, by means of an 
adenoviral vector, restored normal PAI-1 expression, and led these 
researchers to suggest that Smad7 deficiency may play a central role in the 
TGF-β1 hyperresponsiveness, and subsequent fibrosis, observed in 
scleroderma (Dong et al. 2002).   
 
Removing this key negative regulator of the profibrotic pathway results in an 
imbalance between activating and inhibitory Smad signals, leading to 
prolonged signalling in response to TGF-β1, excessive deposition of ECM 
components and, ultimately, to fibrotic disease (Takagawa et al. 2003; Varga 
et al. 2002).  This imbalance may also result, however, from inappropriately 
high levels of transcriptionally active R-Smads, such as Smad3 (Dong et al. 
2002). 
 
Because Smad proteins lack enzyme activity, the Smad cascade is not 
amplified.  As a result, the duration and intensity of signalling in response to 
TGF-β1 is extremely sensitive to alterations in the levels of the different Smad 











scleroderma fibroblasts to downregulate the transcriptional activator, Smad3, 
in response to prolonged TGF-β signalling, results in constitutive activation of 
the Smad pathway, leading to the pathological accumulation of Smad-
inducible gene products (Mori et al. 2000; Mori et al. 2003).   
 
Immunohistological analysis of scleroderma skin lesions performed by Dong 
et al. (2002) further supported these findings, demonstrating markedly 
increased Smad3 staining in biopsies taken from sclerotic lesions, relative to 
those taken from normal tissues.  These elevated expression levels were also 
associated with increased R-Smad phosphorylation, indicative of hyperactive 
TGF-β1 signalling.  Taken together with the deficiency in Smad7 expression 
mentioned above, it seems evident that the ratio of R-Smads to I-Smads is 
dramatically perturbed in systemic sclerosis.  This may provide a model for 
the molecular mechanism of fibrosis seen in other disorders (Dong et al. 
2002). 
 
Ligand-independent phosphorylation and nuclear accumulation of R-Smads 
have also been demonstrated to cause fibrosis – in both the liver and in 
fibroblast cultures taken from patients with systemic sclerosis (Varga et al. 
2002).  In these cases, disruption of the microtubule cytoskeletal network 
prevents cytosolic retention of the R- and Co-Smads, leading to transcriptional 
upregulation of profibrotic gene targets by R-Smad/Co-Smad complexes 
which accumulate in the nucleus, in the absence of TGF-β1 signalling (Dong 
et al. 2000). 
 
Based on their observed role in fibrotic disease, therefore, the R-Smads 
(Smad2 and -3) and the inhibitory Smad7 were prioritised as candidates for 
investigation.  The phosphorylation state of Smad3 (indicative of the level of 















2.4  Previous Research and Rationalé for this study 
Previous research performed on this family involved linkage-based exclusion 
mapping (see 2.2.1), to determine the presence of a conserved TGFB1 
haplotype in all affected individuals.  Additionally, the coding region and a 
538bp portion of the regulatory region of TGFB1 (incorporating an upstream 
promoter and negative regulatory element) were sequenced, in an affected 
and an unaffected family member, to identify potential disease-causing 
mutations.  The results indicated that the chromosomal region surrounding 
TGFB1 in affected individuals had not undergone meiotic recombination, 
suggesting that affected individuals may share a conserved copy of the gene.  
However, mutation screening failed to demonstrate the presence of a causal 
genetic mutation in either the proximal regulatory or coding regions of TGFB1.  
Out of six polymorphisms identified, only three segregated with the disease, 
all of which were common variants and were therefore unlikely to be 
responsible for the novel phenotype observed (Hartmann 2006). 
 
It was therefore hypothesised that the disease-causing defect may lie in a 
region of TGFB1 not yet investigated (for instance, in a distal 
enhancer/repressor sequence or in a splice donor/acceptor site), or in a 
different, but related component of the fibrotic pathway.  For this reason, the 
decision was made to examine the TGFB1 transcript, for alterations in 
structure (indicative of whole exon deletions or splice-site aberrations, which 
could not be detected by direct exonic sequencing), and expression 
(indicative of alterations in distal regulatory sequences). 
 
Downstream signalling components with a proposed role in fibrotic disease, 
were investigated at the protein level (in the case of Smad2 and -3) or the 
transcriptional level (in the case of Smad7), to determine whether alterations 
in expression could account for the excessive fibrosis observed.  TGF-β1 













2.5 Aim and Objectives  
The aim of this project was to determine the role of TGFB1 and the Smad 
proteins in the molecular basis of the novel familial fibrotic disease described 




1.     Determine mRNA expression levels of TGFB1 in cultured fibroblasts 
from an affected and an unaffected individual, using quantitative real-
time PCR. 
 
2. Identify possible splice-site mutations and/or whole exon deletions by 
comparing the length and sequence of the TGFB1 transcript in an 
affected and an unaffected individual. 
 
3.     Quantify basal and TGF-β1-inducible levels of downstream signaling 
components (Smad2/3 and 7) in fibroblast whole cell lysates from an 
affected and an unaffected individual by immunoblotting (“western 
blot”) and quantitative real-time PCR. 
 
4. Analyse the cellular response to TGF-β1 stimulation, by comparing 
basal level of Smad phosphorylation to the stimulated level following 











3. Materials and Methods 
 
3.1 Analysis of TGFB1 mRNA 
The TGFB1 transcript was examined to investigate the possibility that splice 
variants, or elevated expression levels of TGFB1 could account for the 
observed symptoms in affected individuals.  Total RNA from cultured 
fibroblasts of an affected (RTSAD1.3) and an unaffected individual 
(RTSAD1.4) (Fig.1) was reverse-transcribed to yield cDNA, from which the 
TGFB1 transcript was analysed for length and sequence aberrations and for 
differences in expression levels between the individuals. 
 
3.1.1 Cell Culture 
Human skin fibroblasts were cultured from punch biopsies taken from family 
members RTSAD1.3 (affected son) and RTSAD1.4 (unaffected mother), after 
informed consent had been obtained (UCT Research Ethics Committee 
Number 492/2007).  Cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (SIGMA-ALDRICH, Missouri, USA or GIBCO®, Invitrogen 
Corporation, California, USA), containing 1000mg/L D-glucose, 4mM L-
Glutamine, 110mg/L Sodium Pyruvate, and 10% Foetal Calf Serum (SIGMA-
ALDRICH or GIBCO®) at 37°C, in a humidified atmosphere containing 10% 
CO2. 
 
3.1.2 Isolation of Total RNA from Fibroblasts 
Cultured RTSAD1.3 and RTSAD1.4 fibroblasts, at passage seven, were 
washed with 1x sterile-filtered Phosphate Buffered Saline (PBS) (Bioshop 
Canada Inc., Ontario, Canada), treated with trypsin-EDTA (SIGMA-ALDRICH)  
for 2 minutes at 37°C, and washed again with 12ml DMEM (SIGMA-
ALDRICH), followed by centrifugation for 10 minutes at 1000rpm in an MSE 
bench-top centrifuge (Henderson Biomedical Ltd., UK).  The cell pellet was 
resuspended in 10ml sterile filtered 1x PBS (Bioshop Canada Inc.), and 
centrifuged for a further 10 minutes at 1000rpm.  After aspiration of the 
supernatant, total RNA was isolated from the cell pellet using the High Pure 












manufacturer’s instructions (Appendix D).  Isolated RNA was stored at -80°C 
in 10µl aliquots. 
 
The concentration of RNA samples was determined using the NanoDrop 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).  The 
integrity of the RNA was also ascertained by subjecting 10µl of each sample, 
mixed with 3µl of loading buffer (Appendix A), to agarose gel electrophoresis 
for 20min at 120V, on a 1% agarose low electroendosmosis gel (Roche 
Diagnostics) using Tris-Borate EDTA Electrophoresis Buffer (TBE) (891.8mM 
Tris base; 889.4mM Boric Acid; 19.9mM EDTA, pH8), and incorporating 
Ethidium Bromide (SIGMA-ALDRICH) (0.5µg/ml) for visualisation (Appendix 
A).  To determine the relative molecular mass of the bands observed, 500ng 
of the Gene Ruler™ 100bp DNA Ladder Plus Molecular Weight Marker 
Improved (Fermentas International Inc., Hanover, USA) (Appendix B) was 
included as a size standard.  DNA was visualised after electrophoresis using 
the UVIPro Gel Documentation System (UVITec, Cambridge, UK), and 
images were acquired using UVIPro software v12.3 for Windows (Copyright 
1999-2005 UVITec). 
 
3.1.3 cDNA Synthesis 
cDNA was synthesised from 1µg of total RNA extracted from fibroblasts, using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche).  In order to 
maximise the possibility of generating full-length cDNA, oligo(dT)18 primers 
complementary to the mRNA poly(A) tail were used, and the manufacturer’s 
instructions were followed (Appendix D).  Denaturation of the template-primer 
mix was performed on a Touchdown Thermal Cycler (ThermoHybaid, 
Middlesex, UK), while the reverse transcription and inactivation steps were 
performed using a Px2 Thermal Cycler (ThermoHybaid).  The resulting cDNA 
was stored at -20°C. 
 
The concentration of cDNA samples was determined using the NanoDrop 
Spectrophotometer (NanoDrop Technologies).  Where necessary (for 
instance, in the case of cDNA synthesised from RNA retrieved after break 











subjecting a 5µl aliquot of each sample (mixed with 3µl loading dye) to 
agarose gel electrophoresis on a 1% agarose gel in TBE buffer (containing 
0.5µg/ml Ethidium Bromide) and visualisation under UV light (as described in 
3.1.2). For approximate size determination, 500ng of the Gene Ruler™ 100bp 
DNA Ladder Plus Molecular Weight Marker Improved (Fermentas) was 
included. 
 
Newly-synthesised cDNA was checked for possible genomic contamination by 
polymerase chain reaction (PCR), using primers designed to amplify exon 3 of 
TGFB1 (Forward: 5’- TCAGTTAGTGTATGTGGGGTCG -3’; Reverse: 5’- 
GTCTCAGCACTTTCACACCAG -3’), which had previously been synthesised 
using the Beckman 1000M DNA Synthesizer in the Department of Molecular 
and Cell Biology, UCT.  These primers are complementary to intronic regions 
flanking exon 3; thus amplification should only occur in the presence of 
genomic DNA, since cDNA contains no introns. 
 
The PCR reaction mixture contained 1X GoTaqTM Reaction Buffer (1.5mM 
MgCl2, pH8.5) (Promega, Madison, WI, USA), forward and reverse primers 
(0.4µM each), deoxyribose nucleotide triphosphates (dNTPs) (Bioline, 
Michigan, USA) (0.2µM each), 1µl of template (either RTSAD1.4 genomic 
DNA at 100ng/µl, or RTSAD1.4 cDNA of variable concentration) and 0.5 Units 
(U) of GoTaqTM DNA polymerase (Promega), in a final volume of 25µl.  PCR 
contamination was determined by the inclusion of a DNA-free water control, in 
which distilled water was substituted for the template.  This reaction mix, 
hereafter referred to as the “Standard Reaction Mix”, is listed in Table 1, and 



















Table 1. Standard PCR mix (for a final volume of 25µl) 
Reagent   Final Concentration 
Forward Primer 0.4µM 
Reverse Primer 0.4µM 
dNTPs (Bioline) 0.2µM 
GoTaq Buffer (Promega) 1X 
GoTaq DNA Polymerase (Promega) 0.5U 
 Template (genomic DNA or cDNA) 4ng/µl 
 
Reaction conditions were as follows:  An initial denaturation step at 95°C for 5 
minutes, followed by thirty cycles of 95°C for 30 seconds, 58°C for 30 
seconds, and 72°C for 30 seconds, with a final 7 minute elongation step at 
72°C.  The reaction was performed on a Px2 Thermal Cycler (ThermoHybaid). 
 
After the addition of 5µl loading dye, PCR products were electrophoresed on a 
1% agarose gel in TBE buffer, incorporating 0.5µg/ml Ethidium Bromide 
(SIGMA-ALDRICH), for 20 minutes at 120V, and visualised under UV light as 
previously described (3.1.2).  As before, 500ng of the Gene Ruler™ 100bp 
DNA Ladder Plus Molecular Weight Marker Improved (Fermentas) was 
included as a size standard, to determine the molecular mass of the bands 
observed. 
 
3.1.4 Determination of TGFB1 Transcript Length and Sequence 
Since the presence of splice variants or whole exon deletions could lead to 
length and sequence aberrations, the length of the TGFB1 transcript was 
verified by agarose gel electrophoresis, and the entire transcript sequenced in 
both an affected and an unaffected individual. 
 
3.1.4.1 Primer Design 
The TGFB1 mRNA reference sequence was obtained from the NCBI 
database (http://www.ncbi.nlm.nih.gov/, GeneID 7040, accession number 
NM_000660). Information about the TGFB1 gene, including the complete 
DNA sequence, had previously been retrieved from the NCBI and Ensembl 
(www.ensembl.org) databases (NCBI accession number NC_000019.8, sub-











annotation programme, Annot v9 (Dr George Rebello, personal 
communication).  This annotated gene sequence, which included the 
positions of SNPs, splice sites, exons and introns, was used to map exon 
boundaries onto the mRNA.  Based on this gene annotation, primers were 
designed to amplify the shortest possible cDNA fragment that included every 
exon boundary. 
 
Suitable oligonucleotide pairs, of between 18 and 22 bases in length, with a 
GC content of 45-65% were identified from the mRNA sequence (in the case 
of forward primers) and its reverse complement (in the case of reverse 
primers), and subjected to a sequence similarity search, using the genomic 
DNA and reference mRNA databases available at NCBI BLAST (Basic Local 
Alignment Search Tool) (www.ncbi.nlm.nih.gov/BLAST).  Those oligo-
nucleotides whose sequences appeared to be unique to the TGFB1 transcript 
were analysed further.  The melting temperatures of primer pairs were 
matched using OligoCalculator (http://trishul.sci.gu.edu.au/tools/ 
OligoCalculator.html) and the potential formation of hairpin, homo- and 
heterodimer structures, was analysed using OligoAnalyzer (Integrated DNA 
Technologies, (www.idtdna.com/analyzer/Applications/OligoAnalyzer/Default. 
aspx)   
 
Two primer pairs were finally selected (Table 2).  The first pair (F1 and R1), 
were positioned in exons 1 and 7 respectively, generating an amplicon of 
1608bp in length, which covered all exon-exon boundaries.  This amplicon is 
referred to hereafter as the “whole transcript”.  Since these primers were too 
far apart to allow for adequate sequencing of the transcript, a second, internal 
primer pair (F2 and R2) was designed, amplifying a 985bp fragment, 
representing exons 1 to 6 of the transcript and overlapping slightly with the 
region which had been sequenced using F1 and R1.  This amplicon is 
referred to hereafter as the “internal fragment”.  Primers were synthesised 
using the Beckman 1000M DNA Synthesizer in the Department of Molecular 
and Cell Biology, UCT.  The positions of the primers on the mRNA reference 












Table 2. Primers used to amplify TGFB1 transcript.  The melting temperature of each primer 
and the expected amplicon sizes (based on the NCBI reference sequence) are also indicated. 







F1  5'- CTACACGGCGTCCCTCAGG-3' 64 
1608bp 
R1  5'- GCAGGAGCGCACGATCATGTTG -3' 70 
Internal 
Fragment 
F2  5'- CTACCTTTTGCCGGGAGACC-3' 64 
985bp 
R2  5'- GCAGCAGTTCTTCTCCGTGG-3' 64 
 
3.1.4.2 PCR Optimisation 
PCR reactions are optimised by the alteration of a single parameter at a time, 
so that the effect of each individual alteration on the efficiency of the reaction 
can be determined.  These parameters may include annealing temperature, 
Magnesium Chloride (MgCl2) concentration, pH, the addition of additives such 
as Dimethyl Sulphoxide (DMSO), or the manipulation of other reaction 
conditions (denaturation and elongation times and temperatures). 
 
For both the whole transcript and internal fragment, optimisation involved 
determination of the optimum annealing temperature for the amplification of 
each fragment.  For the purposes of PCR, the melting temperature (Tm) of 
each primer was calculated manually using the formula Tm = 4(G+C) + 
2(A+T), and the annealing temperature (Ta) was estimated to be 5°C lower 
than the lower Tm of the pair.  A temperature gradient was then selected, 
based on these calculations.  In both cases, the gradient consisted of three 
reaction tubes, one with an annealing temperature corresponding to the 
optimum calculated (59.4°C), and the other two with annealing temperatures 
approximately 2°C above or below the calculated optimum (57.3°C and 
61.6°C respectively). 
 
The standard reaction mix described in Table 1 was used, with the exception 
of the template. In this case, 1µl of cDNA from the unaffected individual 
(RTSAD1.4) was used for optimisation.  A template-free control, in which 1µl 











contamination, and was subjected to an annealing temperature of 59.4°C.  
The temperature gradient PCR was performed on the Px2 Thermal Cycler 
(ThermoHybaid), with the following reaction conditions: 95°C for 5 minutes, 
followed by 35 cycles of 95°C for 60 seconds, Ta (57.3°C, 59.4°C or 61.6°C) 
for 60 seconds and 72°C for 80 seconds.  A final elongation step at 72°C for 7 
minutes completed the reaction.   
 
3.1.4.3 Agarose Gel Electrophoresis 
Following the temperature gradient PCR, the PCR products (25µl) were each 
mixed with 5µl loading buffer, and electrophoresed on a 1% agarose gel in 
TBE buffer, containing 0.5µg/ml Ethidium Bromide (SIGMA-ALDRICH), for 40 
minutes at 110V and visualised under UV light as previously described 
(3.1.2).  To determine the molecular mass of the bands observed, 500ng of 
the Gene Ruler™ 100bp DNA Ladder Plus Molecular Weight Marker 
Improved (Fermentas) was included as a size standard.   
 
The optimum annealing temperature was determined to be that temperature 
at which the relevant band on the agarose gel showed either the brightest 
fluorescence, indicative of a high concentration of PCR product, or, where all 
bands were equally bright, the least amount of non-specific amplification.   
 
3.1.4.4 PCR in Family Samples 
Following optimisation, each amplicon was amplified from RTSAD1.3 
(affected) and RTSAD1.4 (unaffected negative control) cDNA.  The Standard 
Reaction Mix was used, with primers specific to the amplicon of interest, and 
1µl of template cDNA (variable concentration) per reaction.  PCR reactions 
were performed in duplicate, to counteract loss of PCR product sustained 
during gel extraction (see 3.1.4.5).   
 
DNA Fragments were amplified on a Px2 Thermal Cycler (ThermoHybaid) 
using the following cycling conditions: 95°C for 5 minutes, 35 cycles of 95°C 
for 60 seconds, Ta (amplicon-specific, determined during optimisation) for 60 












3.1.4.5 Determination of Amplicon Length and Preparation of PCR Products 
for Sequencing  
PCR products (25µl combined with 5µl Loading Buffer) were electrophoresed 
for 40 minutes at 110V on a 1% agarose gel (in 1X TBE) incorporating 
0.5µg/ml Ethidium Bromide.  As in previous cases, the Gene Ruler™ 100bp 
DNA Ladder Plus Improved (0.05µg/µl) (Fermentas) was included for size 
determination.  Gels were viewed using a UV transilluminator (UVITec), and 
images were acquired using UVIPro software v12.3 for Windows.  At this 
point, the size of the PCR product generated from the cDNA of the affected 
individual (RTSAD1.3) was compared to that of the unaffected individual, 
based on their electrophoretic mobility, relative to that of the Gene RulerTM 
size standard.  Both were then checked against the expected length of the 
amplicon (based on the NCBI reference sequence, accession number 
NM_000660) to detect possible variations. 
 
Agarose blocks containing the PCR products were excised from the gel under 
UV light.  Since PCR reactions had been performed in duplicate, bands 
containing amplified cDNA from the same individual were pooled.  PCR 
products were purified from the agarose using the QIAquick® Gel Extraction 
Kit (QIAGEN, Hilden, Germany).  Manufacturer’s instructions for 
microcentrifuge extraction were followed, except for the final elution step, in 
which an equivalent volume of distilled water was substituted for the supplied 
elution buffer (Appendix D). 
 
3.1.4.6 Agarose Gel Quantification of PCR Products 
A 5µl aliquot of each PCR product extracted from agarose (mixed with 3µl 
loading dye) was subjected to agarose gel electrophoresis for 40 minutes at 
110V, on a 1% agarose (0.5µg/ml Ethidium Bromide) gel in 1X TBE Buffer, 
and viewed using the UVIPro Gel Documentation System (UVITec).  The gel 
was photographed using UVIPro software v12.3 for Windows (UVITec) and 
analysed using UVISoft UVIBand Windows Application v11.9 (UVITec).  The 
amount of PCR product contained in each band in the agarose gel was 
determined from its fluorescent intensity, relative to the fluorescent intensity of 











Marker Improved (Fermentas), for which the quantity of DNA was known 
(supplied by the manufacturer – see Appendix B).  From this value, the 
concentration of PCR product retained after gel extraction could be 
calculated. 
 
3.1.4.7 Cycle Sequencing 
Cycle sequencing was performed using the ABI PRISM® BigDyeTM Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems), following manufacturer’s 
instructions outlined in the Automated DNA Sequencing Chemistry Guide 
(Applied Biosystems, Copyright 1998).  The reagents and their concentrations 
(in a final volume of 10µl) are listed in Table 3.  Because of the extreme length 
of the fragments sequenced (~1kb), approximately 100ng of PCR product was 
used per reaction.  The concentrations of Terminator Mix and Sequencing 
Buffer used were those recommended for a full reaction (for fragments 
>500bp in length), while 1µM of primer (forward or reverse) was used for each 
reaction.   
 
Table 3. Reagents and quantities added to the cycle sequencing reaction (Final volume 10µl). 
Reagent Concentration/Amount 
PCR Product 100ng 
Primer (Forward or Reverse) 1µM 
BigDyeTM Terminator Mix 4.0µl 
Sequencing Buffer 1.0 µl 
 
Reaction conditions were as follows: an initial denaturation step at 98°C for 5 
minutes, followed by 30 cycles of 96°C for 10 seconds, 50°C for 5 seconds 
and 60°C for 4 minutes.  Cycle sequencing was performed on the GeneAmp 
9700 PCR System (Applied Biosystems). 
 
3.1.4.8 Ethanol Precipitation 
Following cycle sequencing, the amplified DNA was purified from 
contaminating reagents (such as dNTPs, excess primer or DNA polymerase) 
by subjecting the reaction mixture to ethanol precipitation.  Two microlitres of 











CA, USA) and 2.5 volumes of 100% ethanol were added to the reaction 
mixture, which was incubated at -20°C for at least 2 hours.  This mixture was 
centrifuged for 10 minutes at 10 000rpm on an Eppendorf 5145D 
microcentrifuge (Eppendorf, Hamburg, Germany).  The supernatant was 
discarded, and the pellet resuspended in 20µl 70% ethanol, followed by a 
second centrifugation step for 10 minutes at 10 000rpm.  The supernatant 
was again discarded and the pellet left to air dry for at least 1 hour at room 
temperature.  Finally, the pellet containing purified, amplified PCR product for 
sequencing, was resuspended in 10µl Hi-DiTM formamide (Applied 
Biosystems). 
 
3.1.4.9 Automated DNA Sequencing 
Automated sequencing was performed on the ABI PRISM® 3100 Genetic 
Analyzer (Applied Biosystems) at 60°C, using the POPTM-6 separation 
polymer (Applied Biosystems) (França et al. 2002).  To obtain the longest 
possible readable sequence, sequencing was repeated several times for each 
primer, extending the analysis period on the machine where necessary.   
 
Sequencing results were collected using ABI PRISM® 3100 Data Collection 
software (Applied Biosystems), and analysed initially using Sequencing 
Analysis v3.7 software (Copyright 1989-2001, Applied Biosystems). For each 
amplicon, sequences generated using either the forward or reverse primers 
were edited, reverse complemented where applicable, and aligned with the 
reference sequence (obtained from NCBI) using the ClustalW Multiple 
Alignment accessory application available in BioEdit Sequence Alignment 
Editor v7.0.0. 
 
3.1.5 Real-time (Quantitative) PCR of TGFB1 Transcript 
To determine whether TGFB1 was overexpressed in affected individuals, 
TGFB1 transcript levels in cultured RTSAD1.3 and RTSAD1.4 fibroblasts 













SYBR Green is a DNA-binding dye, which emits fluorescent light of 
wavelength 530nm upon intercalation with double-stranded DNA.  Thus, it can 
be used to measure the generation of PCR products in real time, as its 
fluorescent emission is proportional to the amount of double-stranded product 
present in the reaction tube.  In qPCR, fluorescence is measured by the real-
time PCR instrument (in this case, the LightCycler 1.5) at the end of the 
elongation step of every cycle, to monitor the increase in amplified product 
produced (Roche Applied Science LightCycler® DNA Master SYBR Green I 
Handbook, Roche Diagnostics, Mannheim, Germany). 
 
The cycle in which the first significant increase in fluorescence (above the 
background fluorescence present at the start of the PCR reaction) is detected, 
is referred to as the crossing point, or threshold cycle (CT), and is used as a 
tool for calculating the starting amount of template in each sample.  Samples 
with a higher starting concentration of template will generate more products in 
a shorter number of cycles, and will therefore have a lower CT (QuantiFast 
SYBR Green PCR Handbook 01/2007, QIAGEN). 
 
However, because SYBR Green binds DNA non-specifically, the formation of 
primer dimers may affect the levels of fluorescence detected during the 
reaction.  To prove that the increase in fluorescence observed is a result of 
specific amplification of the desired product, melting curve analysis may be 
performed following amplification.  As the reaction mixture is heated to 95°C, 
double stranded DNA is denatured, and SYBR Green fluorescence 
decreases.  This decrease in fluorescence is monitored by the qPCR 
instrument, which displays it as a melting curve, with the peak of the curve 
corresponding to the melting temperature of the DNA fragment.  Since length 
and GC content significantly influence the melting temperature of DNA, the 
melting peak of any given fragment is specific to that sequence.  Thus, if the 
PCR reaction generates only one amplicon, only one melting peak will be 
yielded.  However, if primer dimers or non-specific products are present, 
additional melting peaks will be generated, and may also be present in the 
No-Template Control.  Specificity of qPCR, and the presence of primer 











gel electrophoresis, following PCR (Roche Applied Science LightCycler® DNA 
Master SYBR Green I Handbook, Roche Diagnostics). 
 
Analysis of the results generated by qPCR was performed using the 2-ΔΔCT 
method of relative quantification, which describes the expression levels of a 
target gene (in this case, TGFB1) in an experimental group (the affected 
individual), relative to a reference group (the unaffected control individual).  A 
reference gene is incorporated to normalise the PCR reactions for the amount 
of cDNA used as a template (Livak and Schmittgen 2001).  For these 
experiments, the housekeeping gene Glucuronidase Beta (GUSB) was used 
as a reference (Glenn et al. 2007; Lee et al. 2006). 
 
3.1.5.1 Determination of Amplification Efficiencies for Target (TGFB1) and 
Reference (GUSB) Genes 
In order for the 2-ΔΔCT method to be valid, the target and reference genes must 
be amplified with approximately equal efficiencies.  To determine whether this 
was the case, a dilution series was prepared using control cDNA, previously 
synthesised from RNA isolated from blood taken from an unrelated individual, 
using the ImPromII Kit (Promega, supplied by J. Scholefield).  Control cDNA 
was diluted to 100ng/µl, 10ng/µl and 1ng/µl in sterile distilled water, and 
concentrations were confirmed using the NanoDrop spectrophotometer 
(NanoDrop Technologies).  Real-time qPCR was performed in triplicate on 
these cDNA dilutions, using commercially available primer assays for either 
TGFB1 or GUSB. 
 
A master mix, containing the QuantiFast SYBR Green PCR Master Mix 
(QIAGEN), the Quantitect Primer Assay specific to either the target or 
reference gene (QIAGEN) and RNase-free water, as described in Table 4, 
was prepared, mixed thoroughly by vortexing, and aliquoted into precooled 
LightCycler capillaries (Roche Diagnostics).  To each capillary, 2µl of cDNA 
(at a concentration of 100, 10 or 1ng/µl) was added, to give a final reaction 
volume of 20µl.  To determine the presence of primer dimers, or PCR 
contamination, a No-Template Control (NTC) was included for each primer 











RNase-free water.  The capillaries were sealed and centrifuged at 3 000 rpm 
for 5 seconds, in an Eppendorf 5145D microcentrifuge, before being loaded 
into the LightCycler sample carousel (Roche Diagnostics). 
 
Table 4. qPCR Reaction Mix (for a final volume of 20µl) 
Reagent Volume Final Concentration 
2xQuantifast SYBR Green PCR Master Mix 
(QIAGEN) 
10µl 1x 
10x Quantitect Primer Assay (QIAGEN) 
GUSB or TGFB1 
2µl 1x 
RNase-free water (QIAGEN) 6µl - 
Template cDNA (or RNase-free water) 2µl variable 
 
The following reaction conditions were used:  activation programme (95°C for 
5 minutes), amplification and quantification programme, repeated 35 times 
(95°C for 10 seconds, 60°C for 30 seconds, with a single fluorescence 
measurement, acquired during annealing), melting curve analysis programme 
(95°C for 0 seconds, 50°C-95°C, with a heating rate of 0.1°C per second and 
a continuous fluorescence measurement) and a final cooling step to 40°C.  
This is summarised in Table 5, and is referred to hereafter as the “standard 
qPCR reaction conditions”.  Quantitative PCR was performed using the 
LightCycler 1.5 (Roche Diagnostics), and amplification and melting curves 
were analysed using LightCycler Software v3.5 (Roche Diagnostics).  






















Table 5. Standard qPCR Reaction Conditions 







None 1 1 95°C 5min none 
Amplification 
Quantification 35 Denaturation 95°C 10s None 
Annealing 60°C 30s Single  
Melting Curve 
Melting Curves 1 Denaturation 95°C 0s None 
Annealing 50°C 30s None 
Melting 95°C 0s Continuous 
Cooling 
None 1 1 40°C 30s none 
 
Results were exported to Microsoft Office Excel 2003 (Copyright 1983-2003 
Microsoft Corporation). For each cDNA dilution, the mean crossing point (CT) 
was determined, for both GUSB and TGFB1, and the ΔCT was calculated (CT, 
TGFB1 – CT,GUSB).  The ΔC T was then plotted against the log of cDNA 
concentration.  If the absolute value of the slope generated is close to zero 
(<0.1), then the amplification efficiencies of the target and reference genes 
can be said to be similar, and the 2-ΔΔCT method of relative quantification can 
be used with confidence (Livak and Schmittgen 2001).  
 
3.1.5.2 qPCR from Family Samples 
Following efficiency calculations, qPCR amplification of both GUSB and 
TGFB1 was performed, using cDNA prepared from the affected (RTSAD1.3) 
and unaffected (RTSAD1.4) family members.  The qPCR master mix 
described in Table 4 was used, and capillaries were prepared as described in 
3.1.5.1.  Two microlitres of template cDNA, at a concentration of 100ng/µl, 
was added to each capillary except in the case of the NTCs, in which 2µl of 
water was substituted for cDNA.  For each sample (RTSAD1.3 or RTSAD1.4), 
reactions were performed in triplicate and repeated twice.  Amplification was 
performed using the standard qPCR reaction conditions, on the LightCycler 











3.1.5.3 Analysis using the 2 -ΔΔCT Method 
Analysis of the results of qPCR performed on the family samples was done by 
means of the 2-ΔΔCT method described by Livak and Schmittgen (2001).  
Crossing points determined from replicate qPCR reactions were averaged, to 
obtain a mean crossing point and a standard deviation.  A maximum standard 
deviation of 0.4 was deemed acceptable, and outlying values were 
disregarded.  For each individual (RTSAD1.3 and RTSAD1.4), the average CT 
for GUSB was subtracted from the average CT for TGFB1, to obtain the ΔCT.  
These values were then used to calculate ΔΔC T, by subtracting the ΔC T for 
RTSAD1.4 from the ΔCT for each sample (RTSAD1.3 and RTSAD1.4).  The 
fold change in expression was determined using the formula 2-ΔΔCT. 
 
These calculations can be summarised in Equation [1] and [2] as follows: 
 
ΔΔCT = (CT, TGFB1 – CT, GUSB)individual X – (CT, TGFB1-CT, GUSB)RTSAD1.4,  [1] 
 
where individual X may be either RTSAD1.3 or RTSAD1.4, and 
 
fold change in TGFB1 expression= 2-ΔΔCT,     [2] 
 
relative to RTSAD1.4.  Standard deviations were carried over from ΔC T to 
ΔΔCT, and were used to create a range for the fold change (by calculating 2-
ΔΔCT for ΔΔCT±SD). 
 
3.1.5.4 Statistical Analysis 
Statistical analysis of the fold change in TGFB1 expression between the 
individuals was performed in Microsoft Excel (Copyright 2003, Microsoft 
Corporation), using the Student’s t-test for unpaired samples.  A two-tailed 
distribution, assuming unequal variances, was used to analyse the data.  














3.1.5.5 Determining Specificity of qPCR and Checking for the Presence of 
PCR Contamination 
For each qPCR reaction performed, 10µl each of representative PCR 
products (one replicate per individual per gene, and one no-template control 
per gene) was mixed with 3µl loading buffer (Appendix A), and 
electrophoresed on a 1% agarose gel in TBE buffer, containing 0.5µg/ml 
Ethidium Bromide, for 40 minutes at 110V, and visualised under UV light as 
previously described (3.1.2).  To determine the molecular mass of the band(s) 
observed, 500ng of the Gene Ruler™ 100bp DNA Ladder Plus Molecular 
Weight Marker Improved (Fermentas International Inc.) was included as a 
size standard.  The number and size of bands, as well as the presence or 
absence of PCR product in no-template control reactions (indicative of PCR 
contamination) were noted.   
 
Additionally, melting curves for each reaction were examined, and the melting 
temperature (an indication of the product size) and number of peaks were 
determined.  Where contamination was present, elimination measures were 
carried out.  These included changing reagents, equipment and the location of 
pre-PCR preparation. 
 
3.2 Analysis of the Smad Signalling Pathway 
To determine whether aberrant expression or phosphorylation of components 
of the Smad signalling cascade could account for the fibrotic phenotype, the 
basal and TGF-β1-inducible levels of relevant Smads (Smad2/3 and -7, as 
well as phosphorylated Smad3) in skin fibroblasts were compared in affected 
and unaffected family members and appropriate unrelated controls, by means 
of western blotting and qPCR. 
  
3.2.1 Cell Culture 
As previously described, primary human fibroblast cultures were established 
from punch biopsies.  These were taken either from unaffected, unrelated 
anonymised controls (in the case of optimisation experiments), or from family 











matched controls (Control 2 and Control 1, respectively), after informed 
consent had been obtained.  Cells were cultured in DMEM (SIGMA-ALDRICH 
or GIBCO®), supplemented with 1000mg/L D-Glucose, 4mM L-Glutamine, 
110mg/L Sodium Pyruvate, and 10% Foetal Calf Serum (SIGMA-ALDRICH or 
GIBCO®) at 37°C, in a humidified atmosphere containing 10% CO2. 
 
3.2.2 Protein Extraction 
In all cases, fibroblasts were cultured to passage 4-8 in culture flasks (Corning 
Incorporated, Corning, NY, USA), and washed with 1X sterile-filtered PBS 
(Bioshop Canada Inc.), before treatment with trypsin-EDTA (SIGMA-
ALDRICH) for 2 minutes at 37°C.  Cells were then seeded into 35mm culture 
dishes or 6-well culture plates at an approximate concentration of 100 000 
cells per dish (or well), in DMEM, and grown to 85% confluence.  After 
incubation at 37°C for 30-72hrs, suitably confluent cultures were washed 
twice with sterile filtered 1XPBS (Bioshop Canada Inc.), and incubated 
overnight at 37°C in serum-free DMEM (GIBCO®).  Dishes were divided into 
“treated” and “untreated”, with treated cells receiving 800pM recombinant 
human TGF-β1 (R&D Systems, Minneapolis, MN, USA) for 1hr at 37°C (Dong 
et al. 2002). 
 
Following treatment with TGF-β1, culture medium was aspirated and cells 
were incubated with 100µl 1X Lysis Buffer (Appendix E) for 10 minutes on ice, 
with occasional scraping (cells intended for use in phospho-protein detection 
were flash-frozen on liquid nitrogen, prior to the addition of lysis buffer).  The 
cell lysate was then transferred to a microcentrifuge tube, and centrifuged at 
4°C in a Sigma 302K benchtop centrifuge (Sigma, Germany) for 10 minutes at 
12 000rpm.  The supernatant was transferred to a clean microcentrifuge tube, 
and mixed with 15-20µl of 5X Laemmli sample buffer containing 2-
mercaptoethanol (see Appendix E), to give a final concentration of 1X.  This 
mixture was boiled at 100°C for 5 minutes and centrifuged briefly in a Progen 
24D microcentrifuge (Progen, Mexborough, UK).  Samples were stored at -














Rabbit anti-Smad2/3 and Rabbit anti-phosphoSmad3 primary antibodies were 
obtained from Cell Signalling Technology (Danvers, MA, USA).  Goat anti-
Actin (loading control) primary antibody was obtained from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA).  Goat anti-Rabbit HRP-conjugated 
secondary antibody was obtained from Santa Cruz Biotechnology, while 
Mouse anti-Goat HRP-conjugated secondary antibody was obtained from 
Pierce Biotechnology Inc (Rockford, IL, USA). 
 
3.2.4 Optimisation of Immunoblotting (“Western Blotting”) 
The first part of the western blot technique involves the separation of 
denatured proteins extracted from cultured cells, on a Polyacrylamide Gel 
matrix, incorporating Sodium Dodecyl Sulphate (SDS) as a denaturing agent.  
This is referred to as SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE).   
The Laemmli buffer system, a variation of SDS-PAGE, was used for all the 
western blot experiments described below.  This is a discontinuous buffer 
system (different buffers are used in the gel and electrode reservoirs), and 
utilises two different percentage acrylamide gels – the stacking (4%) and 
resolving (7.5%) gels – to ensure that samples are compressed into a thin 
starting band and that individual proteins are finely separated and resolved.  
During protein extraction (see 3.2.2), proteins are heated in Laemmli buffer 
(Appendix E), containing SDS and the reducing agent 2-mercaptoethanol.  As 
a result, the denatured polypeptides assume a rod-like shape, with a uniform 
mass:charge ratio, proportional to their molecular weights.  Thus, when 
proteins are electrophoresed, they are separated and migrate according to 
their molecular weights, allowing accurate identification of proteins based on 
size (Mini-Protean ® 3 Cell Instruction Manual, BIO-RAD).    
 
Proteins are then electrophoretically transferred from the gel and immobilised 
onto a nitrocellulose or polyvinylene difluoride (PVDF) membrane to which the 
proteins adhere noncovalently by adsorption.  To maximise the success of 
protein transfer, the buffer system contains a conductive, buffering agent 
(Tris) at an alkaline pH, to maintain the conductivity and pH of the system; 











promote the elution of proteins from the gel (Protein Blotting Guide: A Guide 
to Transfer and Detection, Third Edition, BIO-RAD).   
 
The success of electrophoresis and transfer can be ascertained using a non-
specific anionic dye to visualise all the proteins present on the membrane 
after transfer or by using pre-stained molecular weight markers to monitor 
transfer.   
 
The specific protein of interest is detected using a four-step process.  First, 
unoccupied binding sites on the membrane are blocked to reduce background 
signal, which could result from non-specific binding of either the primary or 
secondary antibody to the membrane.  Next, the membrane is incubated with 
a primary antibody specific to the protein of interest.  A species-specific, 
horseradish-peroxidase (HRP) conjugated secondary antibody is then added, 
which recognises and binds to the primary antibody.  The addition of a 
suitable enzyme substrate, luminol, which is cleaved by HRP, results in the 
production of a chemiluminescent product through oxidation.  The resultant 
light signal is captured by exposure to X-ray film or chemi-imager, allowing for 
specific and sensitive detection of the position of the protein of interest.  The 
molecular weight of this protein can then be estimated, by comparison of its 
electrophoretic mobility to that of various size standards (Protein Blotting 
Guide: A Guide to Transfer and Detection, Third Edition, BIO-RAD). 
 
Several of these steps presented targets for optimisation.  Depending on the 
cross-reactivity of different antibodies, blocking solutions were chosen which 
minimised background signal.  The type of membrane was also altered, from 
PVDF to nitrocellulose, to improve the efficiency of transfer and to reduce 
non-specific antibody binding. 
 
Additionally, the dilution of each primary and secondary antibody (made using 
the appropriate diluent) was optimised, to ensure specificity and to reduce 
background signal.  The optimal antibody concentration was considered to be 











background or non-specific reactions (Protein Blotting Guide: A Guide to 
Transfer and Detection, Third Edition, BIO-RAD). 
 
Incubation time of the membrane with each primary antibody varied, with 
higher affinity antibodies requiring shorter periods of incubation.  Finally, the 
optimal exposure time to either film or chemi-imager was ascertained, in order 
to accurately determine and compare the levels of protein present in each 
sample.  
 
In general, however, the following method was used, and is referred to 
hereafter as the “standard western blot protocol”:  Twenty microlitre aliquots of 
the samples extracted from fibroblasts as described in 3.2.2 were 
electrophoresed on a 7.5% Resolving/4% Stacking Polyacrylamide Gel 
containing 0.1% SDS (Appendix E), at a constant voltage of 150V (maximum 
current 60mA) for 1 hour (or 70 minutes, if two gels were electrophoresed 
simultaneously) in 1X Running Buffer (Appendix E) using the Mini Protean II 
gel apparatus (BIO-RAD).  The Precision Plus Protein Standard Dual Colour 
(BIO-RAD) was included for molecular weight determination (Appendix B). 
 
Following electrophoresis, proteins were transferred to a nitrocellulose 
membrane (Hybond ECL, Amersham plc, Buckinghamshire, UK), at a 
constant voltage of 100V (maximum current 250mA) for 2 hours, in 1X 
Transfer Buffer (Appendix E).  The membrane was washed once for 5 
minutes in TBS containing 0.1% Tween20 (TBST) (Appendix E). Proteins 
were detected after transfer by staining briefly with Ponceau S (0.1% (w/v) 
Ponceau S in 5% acetic acid), and where necessary (as in the case where 
two or more antibodies were being optimised at one time), membranes were 
cut into sections using a scalpel. 
 
After destaining with deionised water, membranes (or membrane sections) 
were blocked with 5% Marvel fat-free milk powder (Premier International 
Foods UK, Ltd.) in TBST for 1 hour at room temperature.  Membranes were 
then incubated with primary antibody (at a dilution determined by optimisation) 










This was followed by a brief rinse in TBST and several washes with TBST (as 
recommended by the antibody manufacturer), to remove excess primary 
antibody.  Membranes were then incubated with secondary antibody (diluted 
in blocking solution) for 1 hour at room temperature. 
 
Following incubation with secondary antibody, membranes were rinsed briefly 
in TBST and then subjected again to several washes with TBST, to remove 
excess antibody. 
 
Finally, membranes were rinsed three times in deionised water and incubated 
in LumiGLO Reserve chemiluminescent substrate (KPL Inc., Gaithersburg, 
MA, USA), consisting of two volumes of Solution B, combined with one 
volume of Solution A for 1 minute.  Excess substrate solution was drained 
from the membrane, which was placed between two sheets of transparency 
film in an X-ray cassette.  Visualisation was performed by exposing the 
membrane to Agfa film (Agfa-Gevaert N.V., Mortsel, Belgium), for various time 
periods. Chemiluminescent detection was also performed using the 
ChemiImager 550 (Alpha Innotech Corporation, USA).  Band density values 
were obtained using the Fluorchem 550 software (Alpha Innotech 
Corporation), following manufacturer’s instructions (Alpha Innotech 
Corporation). 
 
Membranes to be stripped and reprobed with a different antibody were kept 
moist after detection by vacuum sealing in a plastic bag or by placing the 
membrane in TBST in a sealed container and were stored at 4°C until reuse.  
Stripping and reprobing was performed within five days of first use and 
followed the “standard stripping and reprobing protocol”, as follows: 
membranes were incubated with stripping buffer (62mM Tris-HCl pH6.8, 2% 
SDS, 100mM 2-mercaptoethanol, see Appendix E) for 15 minutes at 50°C.  
Stripped membranes were then washed twice with 200ml deionised water and 
the standard western blot protocol was followed from the blocking step.  
Individual membranes were stripped and reprobed up to three times with 












3.2.5 anti-Smad2/3 Western Blot 
Twenty microlitre aliquots of total protein isolated from treated or untreated 
RTSAD1.3, RTSAD1.4 and corresponding age- and sex-matched control 
fibroblasts (see 3.2.2) were subjected to SDS-PAGE, and the standard 
western blot protocol described in 3.2.4 was followed, with the following 
alterations: after blocking, with 5% (w/v) fat-free milk powder in TBST, 
membranes were rinsed with TBST, and washed 3 times, for 5 minutes each, 
with TBST, to remove excess blocking reagent.  Membranes were then 
incubated overnight with primary antibody (Rabbit anti-Smad2/3, Cell 
Signalling Technologies) at a dilution of 1:1000 in 5% (w/v) globulin-free 
Bovine Serum Albumin (BSA) (SIGMA-ALDRICH) in TBST.  Membranes were 
again rinsed, and washed 3 times for 5 minutes each with TBST.  Following 
incubation with secondary antibody (Goat anti-Rabbit, Santa Cruz 
Biotechnology) at a dilution of 1:2000, this washing process was repeated. 
 
3.2.6 anti-phosphoSmad3 Western Blot 
As for Smad2/3, phosphorylated Smad3 was detected in total protein isolated 
from treated and untreated fibroblasts by western blot using the standard 
western blot protocol, with the following alterations:  after blocking, with 5% 
(w/v) fat-free milk powder in TBST, membranes were rinsed with TBST, and 
washed 4 times, for 5 minutes each, with TBST.  Membranes were then 
incubated overnight with primary antibody (Rabbit anti-phosphoSmad3, Cell 
Signalling Technologies) at a dilution of 1:1000, in 5% (w/v) BSA in TBST.  
Membranes were again rinsed, and washed 4 times for 5 minutes each with 
TBST.  Following incubation with secondary antibody (Goat anti-Rabbit, Santa 
Cruz Biotechnology) at a dilution of 1:1000, this washing process was 
repeated.  
 
3.2.7 anti-Actin Western Blot 
Membranes which had previously been probed for one of the Smad proteins 
were stripped, as described in the standard stripping and reprobing protocol, 
and probed with anti-Actin primary antibody, as a loading control.  The 
standard western blot protocol was then followed from the blocking step, with 











primary antibody (Goat anti-Actin, Santa Cruz Biotechnology), at a dilution of 
1:1000 in 5% (w/v) fat-free milk powder in TBST, for one hour.  Membranes 
were then rinsed in TBST, and washed four times, for 15 minutes each, with 
TBST.  After incubation with secondary antibody (Mouse anti-Goat, Pierce) at 
a dilution of 1:2000, this washing procedure was repeated, prior to 
chemiluminescent detection. 
 
3.2.8 Statistical Analysis 
For a single individual, comparisons between basal and TGF-β1-inducible 
levels of either Smad2/3 expression or Smad3 phosphorylation were analysed 
using the Student’s t-test for paired samples.  A two-tailed distribution was 
used, assuming equal variances. 
 
Statistical analysis of the difference in treated:untreated ratios of expression 
or phosphorylation between individuals was performed by means of the 
Student’s t-test for unpaired samples.  A two-tailed distribution was used, 
assuming unequal variances. 
 
In both cases, significance was defined using a type I error, or p-value, of 
0.05.  All tests were performed on Microsoft Excel (Copyright 2003, Microsoft 
Corporation). 
 
3.2.9 Determination of SMAD7 Expression Levels by qPCR 
Basal and TGF-β1-inducible levels of SMAD7 mRNA, in RTSAD1.3 and 
RTSAD1.4 cultured fibroblasts, were determined using qPCR, and the results 
analysed using the 2-ΔΔCt method (Livak and Schmittgen, 2001). 
 
3.2.9.1 Determination of Amplification Efficiencies for Target (SMAD7) and 
Reference (GUSB) genes 
Amplification efficiencies of the target (SMAD7) and reference (GUSB) genes 
were compared as described in 3.1.5.1, using the Master Mix described in 
Table 3, and the standard qPCR reaction conditions (Table 4).  Dilutions of 
control cDNA (100ng/µl, 50ng/µl and 10ng/µl), previously isolated from 











(supplied by J. Meyer), were used to construct the standard curve.  Both 
target and reference genes were amplified from each cDNA dilution in 
triplicate, by means of Quantitect Primer Assays (QIAGEN). 
 
3.2.9.2 Basal SMAD7 Expression in Family Samples 
In order to determine basal mRNA expression of SMAD7 in skin fibroblasts, 
qPCR amplification of the target and reference genes was performed, using 
RTSAD1.3 and RTSAD1.4 cDNA, previously synthesised from RNA extracted 
from fibroblasts which had not been stimulated with exogenous TGF-β1  (see 
3.1.2 and 3.1.3).  The qPCR master mix described in Table 4 was used, and 
capillaries were prepared as described in 3.1.5.1.  Two microlitres of template 
cDNA, at a concentration of 100ng/µl, was added to each capillary, except in 
the case of the NTCs, in which 2µl of water was substituted for cDNA.  
Reactions were performed in triplicate.  Amplification was performed in 
triplicate for each individual, for each gene, using the standard qPCR reaction 
conditions (Table 5), on the LightCycler 1.5 (Roche), and results were 
analysed using LightCycler Software v3.5. 
 
3.2.9.3 Cell Culture, RNA Isolation and cDNA Synthesis 
Skin fibroblasts, taken from biopsies of an affected (RTSAD1.3) and an 
unaffected individual (RTSAD1.4) were cultured as previously described 
(3.2.1).  Cells were cultured to passage 7-9, washed with 1X PBS (Bioshop 
Canada Inc.), and treated with trypsin-EDTA for 2 minutes at 37°C (SIGMA-
ALDRICH), before being seeded into 35mm cell culture dishes.  After 
incubation at 37°C for 48hrs, dishes which had reached 85% confluence were 
washed twice with 1X PBS, and incubated overnight at 37°C in serum-free 
DMEM (GIBCO®).  Dishes were divided into “treated” and “untreated”, with 
treated cells receiving 500pM recombinant human TGF-β1 (R&D Systems) for 
1hr at 37°C (Dong et al. 2002).  Following treatment, medium was aspirated, 
cells were washed with 1X sterile-filtered PBS (Bioshop Canada Inc.), before 
treatment with trypsin-EDTA (SIGMA-ALDRICH).  This was followed by a 
second wash, in 12ml DMEM (SIGMA-ALDRICH), and centrifugation for 10 
minutes at 1000rpm in an MSE bench-top centrifuge (Henderson Biomedical 











(Bioshop Canada Inc.), and centrifuged for a further 10 minutes at 1000rpm.  
The pellet was again resuspended, in 1ml PBS, and centrifuged for 10 
minutes at 13 400rpm in a microcentrifuge.  After aspiration of the 
supernatant, total RNA was isolated from the cell pellet using the High Pure 
RNA Isolation Kit (Roche Diagnostics), following manufacturer’s instructions.  
Isolated RNA was stored at -80°C in 10µl aliquots. 
 
The concentration of RNA samples was determined using the NanoDrop 
Spectrophotometer (NanoDrop Technologies) and the integrity of the RNA 
was ascertained by agarose gel electrophoresis.  Ten microlitres of each 
sample, mixed with 3µl of loading buffer,  was electrophoresed on a 1% 
agarose gel in TBE buffer for 20min at 120V, incorporating Ethidium Bromide 
(SIGMA-ALDRICH) (0.5µg/ml) for visualisation.  To determine the molecular 
mass of the bands observed, 500ng of the Gene Ruler™ 100bp DNA Ladder 
Plus Molecular Weight Marker Improved (Fermentas International Inc.) was 
included as a size standard.  The gel was visualised under UV light as 
previously described (see 3.1.2). 
 
Synthesis of cDNA was performed using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche), following manufacturer’s instructions, and using 
oligo(dT)18 primers, complementary to the mRNA poly(A) tail.  Denaturation of 
the template-primer mix was performed on a Touchdown Thermal Cycler 
(ThermoHybaid, Middlesex, UK), while the reverse transcription and 
inactivation steps were performed using a Px2 Thermal Cycler 
(ThermoHybaid).  The resulting cDNA was stored at -20°C. 
 
Newly-synthesised cDNA was checked for possible genomic contamination 
PCR, using primers designed to amplify exon 3 of TGFB1, as previously 
described (3.1.3).  The standard reaction mix (Table 1) was used, and 
reaction conditions were as follows:  An initial denaturation step at 95°C for 5 
minutes, followed by thirty cycles of 95°C for 30 seconds, 58°C for 30 
seconds, and 72°C for 30 seconds, with a final 7 minute elongation step at 












Following the addition of 5µl loading dye, PCR products were electrophoresed 
on a 1% agarose gel in TBE buffer, incorporating 0.5µg/ml Ethidium Bromide 
(SIGMA-ALDRICH), for 20 minutes at 120V, and visualised under UV light 
(3.1.2).  As before, 500ng of the Gene Ruler™ 100bp DNA Ladder Plus 
Molecular Weight Marker Improved (Fermentas) was included as a size 
standard.  
 
3.2.9.4 TGF-β1 Inducible SMAD7 Expression in Family Samples  
The target (SMAD7) and reference (GUSB) genes were amplified from cDNA, 
prepared from RNA isolated from treated or untreated RTSAD1.3 and 
RTSAD1.4 fibroblasts (see 3.2.9.3).  The qPCR master mix described in 
Table 3 was used, and capillaries were prepared as described in 3.1.5.1.  To 
each capillary, 2µl of undiluted template cDNA was added, at a concentration 
of approximately 1900ng/µl, as determined by the NanoDrop 
Spectrophotometer (NanoDrop Technologies). In the case of the NTCs, 2µl of 
water was substituted for cDNA.  Amplification was performed in duplicate for 
both treated and untreated samples, for each individual, on the LightCycler 
1.5, using the standard qPCR reaction conditions.  Results were analysed 
using LightCycler Software v3.5. 
 
3.2.9.5 Analysis using the 2-ΔΔCT Method 
Analysis of the results of qPCR performed on the family samples was 
performed using the 2-ΔΔCT method (Livak and Schmittgen 2001), as described 
in 3.1.5.3, with Equation [1] modified as follows: 
 
To investigate differences in basal levels of expression: 
 
ΔΔCT = (CT, Smad7 – CT, GUSB)individual X – (CT, Smad7 – CT, GUSB)RTSAD1.4, [1a] 
 
where individual X may be either RTSAD1.3 or RTSAD1.4, and, to investigate 
fold change in SMAD7 expression in response to treatment: 
 
ΔΔCT = (CT, SMAD7 – CT, GUSB)treated – (CT, SMAD7 – CT, GUSB)untreated, [1b] 











Thus, for each individual, basal SMAD7 expression was reported relative to 
RTSAD1.4, while the fold change in expression in response to TGF-β1 
treatment was reported relative to SMAD7 expression in the untreated sample 
for that individual. 
 
3.2.9.6 Statistical Analysis 
Statistical analysis of the fold difference in basal or TGF-β1-inducible SMAD7 
expression between the individuals was performed by means of the Student’s 
t-test for unpaired samples.  A two-tailed distribution was used, assuming 
unequal variances. 
 
The difference between basal and TGF-β1 inducible levels of SMAD7 levels 
for a single individual was analysed using the Student’s t-test for paired 
samples.  A two-tailed distribution was used, assuming equal variances. 
 
In both cases, significance was defined using a type I error, or p-value, of 
0.05.  All tests were performed on Microsoft Excel (Copyright 2003, Microsoft 
Corporation). 
 
3.2.9.7 Determining Specificity of qPCR 
As previously described (see 3.1.5.5), specificity of the qPCR reactions was 
determined by agarose gel electrophoresis and/or analysis of the melting 













4.1 Analysis of TGFB1 mRNA 
The presence of possible disease-causing mutations in TGFB1, such as 
splice-site aberrations, whole exon deletions, or expression defects, was 
investigated by examining the length and sequence of the transcript, and 
determining expression levels of TGFB1 in skin fibroblasts.  This involved 
extraction of total RNA from cultured fibroblasts taken from an affected 
(RTSAD1.3) and an unaffected individual (RTSAD1.4), reverse transcription, 
amplification of the resulting cDNA by conventional PCR and real-time 
quantitative PCR, and analysis of the transcript by means of agarose gel 
electrophoresis and direct sequencing.   
 
4.1.1 Isolation of Total RNA from Fibroblasts 
Total RNA was isolated from RTSAD1.3 and RTSAD1.4 cultured skin 
fibroblasts at passage seven.  To determine the quality and quantity of the 
RNA, aliquots were subjected to agarose gel electrophoresis following 
isolation.   
 
Intact eukaryotic RNA exhibits bright, sharp bands corresponding to the 28S 
and 18S ribosomal RNAs (rRNAs), with the 28S band approximately twice as 
bright as the 18S band, when visualised under UV light.  This 2:1 intensity 
ratio is a good indication of the integrity of the sample, with degraded RNA 
appearing as a smear, lacking both the bright 28S and 18S bands, and the 
2:1 ratio. 
 
Since the rRNA bands could clearly be seen in both samples (RTSAD1.3 and 
RTSAD1.4), and since no smearing was present, the RNA was deemed to be 
intact (Fig.5).  The fluorescent intensity of the bands under UV light indicated 















                               
 
 
Figure 5. Total RNA extracted from RTSAD1.3 and RTSAD1.4 skin fibroblasts, 
electrophoresed on a 1% agarose (0.5µg/ml Ethidium Bromide) gel to determine integrity.  
The positions of the 28S and 18S rRNA bands are indicated with arrows. 1: Gene RulerTM 
100bp DNA Ladder Plus Molecular Weight Marker Improved (Fermentas), 2: RTSAD1.3 RNA, 
3: RTSAD1.4 RNA.   
 
4.1.2 cDNA Synthesis and Checking for Genomic DNA Contamination 
Following isolation, RTSAD1.3 and RTSAD1.4 total RNA was reverse 
transcribed, and the integrity of the resulting cDNA was again checked by 
agarose gel electrophoresis.  Because of the range of different sized 
fragments generated by reverse transcriptase, cDNA appears as a smear on 
the gel.  cDNA synthesised from intact total RNA contains high-, medium- and 
low-molecular weight fragments, generating a longer smear than cDNA 
synthesised from degraded RNA, which consists mainly of low molecular 
weight fragments.   
 
Results such as those shown in Figure 6 suggest sub-optimal template RNA 
integrity, with the breadth of the smear indicating the presence of 
predominantly low molecular weight fragments.  However, since the average 
lengths of the cDNA fragments (determined by comparison with the molecular 
weight marker) exceeded the length of the fragment to be amplified by PCR, it 
was decided that these samples could be used for downstream applications. 
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Figure 6.  cDNA synthesised from isolated fibroblast RNA by reverse transcription, and 
subjected to agarose gel electrophoresis (1% agarose, 0.5µg/ml ethidium bromide) to 
determine integrity.  The size of a reference band in the molecular weight marker is shown.  1: 
Gene RulerTM 100bp DNA Ladder Plus Molecular Weight Marker Improved (Fermentas), 2 to 
5: cDNA synthesised from RTSAD1.3 total RNA. 
 
To determine whether genomic DNA was present in the cDNA samples, after 
isolation and reverse transcription, PCR amplification was performed on a 
sample of RTSAD1.4 cDNA.  This PCR, which had previously been optimised 
on genomic DNA, employed primers complementary to intronic regions 
flanking exon 3 of TGFB1 (Hartmann 2006).  Since cDNA contains no introns, 
it was anticipated that amplification would only occur in the presence of 
contaminating genomic DNA (Fig 7A).  A sample of RTSAD1.4 genomic DNA 
was included as a positive control. 
 
As expected, amplification of exon 3 took place when genomic DNA was used 
as a template.  In the cDNA sample, however, very weak amplification was 
observed (Fig. 7B).  This indicated that a small amount of genomic DNA was 
present.  However, since the primers used for sequencing and qPCR were 
designed to span exon/exon boundaries, making them cDNA-specific, it was 
concluded that the presence of genomic DNA would not affect the results of 
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Figure 7.  PCR using intronic primers to determine the presence of genomic DNA 
contamination. A Position of primers relative to the genomic and cDNA sequences.  Intronic 
primers will only generate a product in the presence of genomic DNA, since cDNA lacks the 
required intronic binding sites. B Products of PCR using intronic primers, designed to amplify 
exon 3 of TGFB1. 1: Gene RulerTM 100bp DNA Ladder Plus Molecular Weight Marker 
Improved (Fermentas), 2: DNA-free water control, 3: RTSAD1.4 genomic DNA positive 
control, 4: RTSAD1.4 cDNA.  The size of a reference band in the molecular weight marker is 
shown. C Design of cDNA-specific primers, across exon/exon boundaries, to prevent 
erroneous amplification from contaminating genomic DNA.  
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4.1.3 Determination of TGFB1 Transcript Length and Sequence 
The presence of splice site mutations in the TGFB1 transcript, which could 
lead to whole exons being skipped or deleted, was examined by agarose gel 
electrophoresis and direct sequencing of cDNA from the affected and 
unaffected family members. 
 
4.1.3.1 Primer Design and PCR Optimisation 
Primers were designed as described in Materials and Methods, to amplify 
either the whole transcript (all seven exons), or an internal fragment, 
corresponding to exons 1 to 6. Optimisation was performed for both of the 
transcript amplicons, using a temperature gradient, and results were 
visualised by means of agarose gel electrophoresis (Fig. 8).   
 
                          
 
Figure 8. Results of temperature gradient PCR, following electrophoresis on 1% agarose 
(0.5µg/ml Ethidium Bromide) gel. Observed fragment sizes are indicated in each case by an 
arrow. The size of a reference band in the molecular weight marker is shown. A Whole 
Transcript amplicon, B Internal Fragment amplicon. 1: Gene RulerTM 100bp DNA Ladder Plus 
Molecular Weight Marker Improved (Fermentas), 2: DNA-free water Control, 3 to 5: PCR 
products generated using annealing temperatures of 57.3°C, 59.4°C and 61.6°C respectively.   
 
A bright band, corresponding to the expected size of the amplified fragment, 
was observed in each lane after PCR and electrophoresis.  It was anticipated 
that the relative fluorescent intensity of the bands in different lanes, when 
viewed under UV light, would vary according to the efficiency of the reaction 
at different annealing temperatures.  The annealing temperature yielding the 
brightest band would then be chosen as the optimum.  However, in both 
















cases, the high intensity of the bands generated at all three of the annealing 
temperatures of the gradient suggested that the PCRs were extremely 
efficient (Fig. 8).  Thus, the annealing temperature which resulted in the least 
non-specific amplification (i.e. the least smearing) was chosen as the 
optimum, in each case.  For the “whole transcript” amplicon, the optimum 
annealing temperature was found to be 57.3°C (rounded to 57°C), while the 
“internal fragment” was optimally amplified at a Ta of 61.6°C (rounded to 
61°C).  
 
4.1.3.2 PCR in Family Samples, Determination of Amplicon Length and 
Preparation for Sequencing 
Following the selection of optimum annealing temperatures for the 
amplification of both fragments, PCR was performed on RTSAD1.3 and 
RTSAD1.4 cDNA.  The products of the PCRs were subjected to agarose gel 
electrophoresis (Fig. 9), and the length of each amplicon was compared 
between individuals, and to the predicted length based on the NCBI mRNA 
reference sequence. 
 
Because of the efficiency of the PCR, yielding a vast amount of PCR product, 
the bands observed after electrophoresis were fairly diffuse, making size 
determination difficult.  However, no apparent difference in size was 
detectable for either amplicon, when the two individuals were compared (Fig. 
9).  In the case of the whole transcript amplicon, bands of approximately 1.5kb 
were observed for both RTSAD1.3 and RTSAD1.4 (compared to the predicted 
1608bp based on the NCBI sequence), while for the internal fragment, 
comparison with the molecular weight marker indicated that the PCR product 
obtained from both individuals was approximately 1kb in length (compared 
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Figure 9. Results of PCR in family cDNA samples, following electrophoresis on a 1% agarose 
(0.5µg/ml Ethidium Bromide) gel, to determine amplicon length. Observed fragment sizes are 
indicated by arrows. The size of a reference band in the molecular weight marker is shown.  A 
Whole Transcript amplicon. B Internal Fragment amplicon. 1: Gene RulerTM 100bp DNA 
Ladder Plus Molecular Weight Marker Improved (Fermentas), 2: DNA-free water control, 3 
and 4: RTSAD1.3, 5 and 6: RTSAD1.4.  PCR product lengths were determined for each 
individual, based on their electrophoretic mobility relative to the size standard. 
 
These bands were excised and purified from the agarose gel, and the amount 
of PCR product present in each was quantified, by subjecting an aliquot of the 
purified product to agarose gel electrophoresis.  Due to the loss of PCR 
product incurred during clean-up, the bands on the quantification gel were 
much sharper, allowing confirmation of the sizes of the amplicons in each 
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Figure 10. PCR products amplified from family cDNA samples, following gel extraction, and 
electrophoresis on a 1% agarose (0.5µg/ml Ethidium Bromide).  Observed fragment sizes are 
indicated by arrows. The size of a reference band in the molecular weight marker is shown. A 
Whole Transcript amplicon. B Internal Fragment amplicon. 1: Gene RulerTM 100bp DNA 
Ladder Plus Molecular Weight Marker Improved (Fermentas), 2 and 3: RTSAD1.3, 4 and 5: 
RTSAD1.4.   
 
4.1.3.3 Sequencing  
Sequences generated for each of the amplicons, using either the forward or 
reverse primers, were compared to the TGFB1 mRNA reference sequence 
obtained from the NCBI database.  Electropherograms were analysed for 
heterozygous changes and ambiguous sequence positions, which were 
replaced with the notation “N”, and edited sequences were then aligned using 
ClustalW, available in BioEdit Sequence Alignment Editor.  Alignments were 
generally created using two or more sequence reads per primer for both 
individuals, to ensure a greater degree of accuracy. 
 
In the case of the “whole transcript” forward and reverse primers, sequencing 
quality declined rapidly after approximately 400bp, leaving a region of 748bp 
internal to the transcript, which could not be sequenced.  Thus, the internal 
fragment primers were employed to sequence this region.  These were 
designed to allow for an overlap between the whole transcript and internal 
fragment sequences, ensuring coverage of all the exon/exon boundaries of 
the transcript (see Appendix C). 
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Positions that differed from the reference sequence in all the forward and/or 
reverse reads for a particular individual were investigated further. The 
presence of these variants in the previously determined RTSAD1.3 and 
RTSAD1.4 genomic DNA sequences was ascertained and, where possible, 
information regarding their effect on the structure and function of TGFB1 and 
its protein product was obtained. 
 
Numerous novel single nucleotide changes were observed in single sequence 
reads of the whole transcript amplicon, for both individuals.  However, when 
examining the alignment generated by several rounds of sequencing, these 
variants could not be confirmed.  It is therefore likely that such apparent 
polymorphisms are in fact sequencing artefacts, or aberrant bases inserted 
during amplification of this particularly long sequence by a non-proofreading 
Taq polymerase.  Excluding these artefacts, two previously published SNPs 
were identified, both of which had previously been found during the 
sequencing of genomic DNA from RTSAD1.3 and RTSAD1.4 (Hartmann 
2006).  
 
In the alignment of sequences generated using the whole transcript forward 
primer, a single heterozygous change (C→T) was observed in exon 1 of the 
transcript, in RTSAD1.3.  This change, which was supported by an identical 
finding in the overlapping region of the internal fragment forward primer 
alignment, was identified as the c. +29T>C polymorphism (rs1982073).  The 
unaffected control, RTSAD1.4, was found to be homozygous (C/C) at the 
























Figure 11.1 Results of sequencing using the whole transcript and internal fragment forward 
primers. A Electropherogram of RTSAD1.3, showing the heterozygous change identified as 
the c.+29T>C polymorphism (indicated by an arrow). B Electropherogram of corresponding 
sequence in RTSAD1.4. C and D BioEdit sequence alignment of sequences generated using 
the whole transcript, and internal fragment forward primers, respectively (Reference: NCBI 
reference sequence for TGFB1 transcript, F: Forward primer, numbers indicate different 
sequencing runs).  The position of the polymorphism is indicated by a block. 
 
The second SNP, a G→C transversion, was identified in the heterozygous 
state in RTSAD1.4, in the alignment produced from sequences generated 
using the internal fragment reverse primer.  This SNP, present in exon 1 of 
TGFB1, was determined to be the c. +74G>C polymorphism, described by 

































Figure 11.2 Results of sequencing using the internal fragment forward primer. A 
Electropherogram of RTSAD1.3. B Electropherogram of corresponding sequence in 
RTSAD1.4, showing the heterozygous change identified as the c.+74G>C SNP (indicated by 
an arrow). C BioEdit sequence alignment of sequences generated using the internal fragment 
forward primer (Reference: NCBI reference sequence for TGFB1 transcript, F: Forward 
primer, numbers indicate different sequencing runs).  The position of the polymorphism is 
indicated by a block. 
 
Combining the sequencing results generated using the whole transcript and 
internal fragment primers, all the exon/exon junctions could be examined.  No 
deviations from the reference sequence were observed in either individual, 
confirming the results of agarose gel electrophoresis (see 4.1.3.2), and 
indicating that splicing and post-transcriptional processing of the TGFB1 











4.1.4 Real-time (quantitative) PCR of the TGFB1 Transcript 
Expression levels of the TGFB1 transcript in fibroblasts taken from an affected 
and an unaffected individual were quantified by qPCR (using SYBR Green 
reaction chemistry), and the results were analysed using the 2-ΔΔCT method.  
 
4.1.4.1 Determination of Amplification Efficiencies for Target (TGFB1) and 
Reference (GUSB) Genes 
For the 2-ΔΔCT method to be valid, the amplification efficiencies of the target 
and reference gene PCRs must be approximately equal.  To confirm whether 
this was indeed the case, the target (TGFB1) and reference (GUSB) genes 
were amplified from serially diluted control cDNA.  For each cDNA dilution, the 
ΔCT values (CT, TGFB1 – CT,GUSB) were plotted against the logarithm of the 
concentration, and the slope of the linear regression line was determined, with 
an absolute value close to zero indicating approximately equal efficiencies.  
As shown in Figure 12, the gradient of the line was found to be 0.0417, 
indicating that the amplification efficiencies of GUSB and TGFB1 were equal, 
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Figure 12. Validation of the ΔΔC T method.  The efficiency of amplification of the target 
(TGFB1) and reference (GUSB) genes was investigated using qPCR.  Serially diluted control 
cDNA (100, 10 and 1ng/µl) was amplified by qPCR using gene-specific primers.  The ΔCT (CT, 
TGFB1 – CT,GUSB) was calculated for each dilution, and plotted against the log of the 
concentration, and the linear regression line was determined using Microsoft Office Excel 
2003.  A gradient with absolute value approximately zero indicates comparable efficiencies. 
 
4.1.4.2 qPCR from Family Samples and Analysis using the 2 -ΔΔCT Method 
Once the amplification efficiencies of the target and reference genes had 
been determined, GUSB and TGFB1 were amplified from RTSAD1.3 and 
RTSAD1.4 cDNA in triplicate, and the crossing points and mean crossing 
points were calculated.  Expression of TGFB1 was normalised to GUSB for 
each individual, by calculating the ΔC T (CT, TGFB1 – CT,GUSB).  The ΔΔC T was 
then calculated using Eq. [1], and the fold change in TGFB1 expression, 















Based on these calculations, no significant difference in normalised TGFB1 








































Figure 13. Normalised TGFB1 gene expression relative to RTSAD1.4 (unaffected individual), 
evaluated using the 2-ΔΔCt method. No significant difference was observed between the 
affected and unaffected individual (p = 0.43).  
 
4.1.4.3 Determining Specificity of qPCR and Checking for the Presence of 
PCR Contamination 
Because SYBR Green binds non-specifically to all double-stranded DNA in 
the reaction vessel, it was necessary to confirm that the increase in 
fluorescence observed during the amplification cycles of qPCR was a result of 
specific amplification of the desired fragment, and not a result of primer 
dimerisation.  Melting curve analysis, performed on the LightCycler (Roche 
Diagnostics) after amplification, yielded a single peak at approximately 80°C 
in the cDNA-containing samples, for each primer pair.  This indicated the 
presence of a single, specifically amplified fragment.  A smaller peak, at 
approximately 75°C, was observed in some of the No-Template controls 
(NTCs), suggesting that primer dimerisation occurred only in the absence of 














Results of the melting curve were confirmed by subjecting representative 
samples (one replicate per individual per primer) to agarose gel 
electrophoresis (Fig. 14).  A single band of the desired size was observed in 
all template-containing reaction tubes, demonstrating specific amplification of 
the desired fragment, while a faint band of low molecular weight, indicative of 
the formation of primer dimer, was only observed in NTCs. 
 








Figure 14. Products of qPCR with GUSB primers, following electrophoresis on a 1% agarose 
(0.5µg/ml ethidium bromide) gel to determine specificity of amplification.  The approximate 
length of the PCR product, as well as the presence of primer dimer in the no template control 
(NTC), is indicated by an arrow. The size of a reference band in the molecular weight marker 
is shown. 1: Gene RulerTM 100bp DNA Ladder Plus Molecular Weight Marker Improved 
(Fermentas), 2 to 4: Products of qPCR from template-containing reaction vessels, 5: No 












  1     2     3     4      5    
100bp 












4.2 Analysis of the Smad Signalling Pathway 
Key components of the Smad signalling cascade were investigated, to 
determine their contribution to the development of the fibrotic phenotype.  
These included the receptor-regulated Smads 2 and 3, whose expression and 
phosphorylation was determined by western blot, and the inhibitory Smad 7, 
which was investigated at the mRNA expression level by means of qPCR. 
 
4.2.1 Western Blot Optimisation 
To ensure optimal protein detection, numerous experimental parameters were 
adjusted, including the type of membrane used for transfer, the dilutions of 
primary and secondary antibody, and the duration of exposure of the 
membrane to either film or chemi-imager. 
 
It was found that nitrocellulose membrane, and in particular, the type of 
membrane designed for enhanced chemiluminescent detection, produced the 
best results, allowing for maximal protein transfer, with minimal background 
signal.  Optimal antibody dilutions generally followed those recommended by 
the manufacturer, with the exception of the secondary antibody concentration 
required for the detection of phosphoSmad3, which was increased from 
1:2000 to 1:1000, in order to increase the intensity of signal.  Finally, the 
duration of exposure of the membrane to the film or chemi-imager varied 
between antibodies, with optimal exposure chosen to be the time at which 
differences in band intensities could be detected and background signal was 
minimised (data not shown). 
 
4.2.2 Smad2/3 Expression in Family and Control Samples 
In order to detect possible aberrations in basal and TGF-β1-inducible 
receptor-associated Smad expression, western blotting was performed, using 
anti-Smad2/3 antibody, on extracts from cultured fibroblasts taken from the 
affected and unaffected family members (RTSAD1.3 and RTSAD1.4) and two 
age- and sex-matched controls.  Comparisons were then made between 












In all the sample lanes, a single band of high intensity was observed, with a 
molecular weight of 60kDa, corresponding to the predicted size of the Smad2 
protein.  An additional lighter band, of approximately 52kDa was assumed to 
be the Smad3 protein.  Results reported refer to the analysis of the Smad2 
band, as it was assumed to be representative of the expression of the 
receptor-regulated Smad proteins. 
 
As can be seen in Figure 15 below, none of the samples displayed marked 
up- or downregulation of Smad2/3, in response to treatment.  This assertion 
was confirmed by statistical analysis of the band densities captured by means 
of the chemi-imager.  Using the Student’s t-test for paired samples, no 
statistically significant difference was observed between the treated and 
untreated samples, for each individual (all p-values ≥ 0.1). 
 
To determine whether Smad2/3 expression differed between individuals, the 
band density ratio of treated:untreated was calculated for each individual, and 
the results compared between the two family members (RTSAD1.3 and 
RTSAD1.4) and between each family member and their respective matched 
control (Control 2 and Control 1, respectively), using the Student’s t-test for 
unpaired samples, assuming unequal variances.  Again, no significant 

































Figure 15. Basal and TGF-β1-inducible Smad2/3 expression in RTSAD1.3, RTSAD1.4, and 
two age- and sex-matched controls (Control 2 and Control 1, respectively).  Whole cell lysates 
from treated (with 800pM TGF-β1 for 1 hour) and untreated fibroblasts were separated by 
SDS-PAGE and transferred to a nitrocellulose membrane. Actin was used as a loading 
control.  Bound antibody was detected by chemiluminescence as described in Materials and 
Methods.  No significant difference in expression was observed between treated and 
untreated samples for each individual, or between the family samples and their respective 
controls. 
 
4.2.3 Smad3 Phosphorylation in Family and Control Samples  
Smad signalling was also examined by means of western blot, using a 
monoclonal rabbit antibody specific to the phosphorylated form of the Smad3 
protein.  As for Smad2/3, western blotting was performed using whole cell 
lysates from treated and untreated fibroblasts, for each of the family members 
and controls.  Comparisons were made between treated and untreated 
samples for each individual, and between individuals, to determine the level of 
Smad3 phosphorylation in response to TGF-β1 treatment. 
 
In all sample lanes, the brightest band detected, at approximately 52kDa, was 
assumed to be phosphorylated Smad3 (Fig. 16).  However, the low 
concentration of this protein in the whole cell lysate necessitated the use of a 
high secondary antibody concentration, in order to ensure detection.  This 
resulted in the detection of numerous non-specific bands and a high 
background signal, making analysis using the chemi-imager less reliable. 
 
TGF-β1     -        +       -       +       -       +       -       + 
  Smad2/3 
       Actin 













Nonetheless, a distinct difference can be seen when comparing the treated 
and untreated lanes for each individual.  Despite the high background signal 
observed in some of the lanes, it appears that phosphorylated Smad3 is 
virtually absent from the unstimulated fibroblasts of all individuals, regardless 
of disease status.  In comparison, however, stimulation with TGF-β1 appears 
to result in a rapid increase in Smad3 phosphorylation (observed as an 
approximate two-fold increase in band density between treated and untreated 
samples) in all individuals, the effects of which are visible after 1 hour of 
treatment. 
 
As for Smad2/3, the ratios of band densities between treated and untreated 
lanes, generated by the chemi-imager, were compared between individuals, 
using the Student’s t-test for unpaired samples, assuming unequal variances.  
Although there appeared to be a difference in levels of phosphorylated protein 
between each family member (RTSAD1.3 and RTSAD1.4) and their matched 
controls (Control 2 and Control 1, respectively), these differences were not 










Figure 16. Basal and TGF-β1-inducible Smad2/3 phosphorylation in RTSAD1.3, RTSAD1.4, 
and two age- and sex-matched controls (Control 2 and Control 1, respectively).  Whole cell 
lysates from treated (with 800pM TGF-β1 for 1 hour) and untreated fibroblasts were 
separated by SDS-PAGE and transferred to a nitrocellulose membrane. Actin was used as a 
loading control.  Bound antibody was detected by chemiluminescence as described in 
Materials and Methods.  A noticeable increase in phosphorylation in response to treatment 
was observed for each individual.  No significant difference in phosphorylation was observed 
between the family samples and their respective controls. 
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4.2.4 Determination of SMAD7 mRNA Expression Levels by qPCR 
The basal and TGF-β1-inducible expression levels of SMAD7 in cultured skin 
fibroblasts of the affected son and his unaffected mother were quantified by 
qPCR (using SYBR Green reaction chemistry), and the results were analysed 
using the 2-ΔΔCT method, as previously described.  
 
4.2.4.1 Determination of Amplification Efficiencies for Target (SMAD7) and 
Reference (GUSB) Genes 
The amplification efficiencies of the target (SMAD7) and reference (GUSB) 
genes were compared, in order to confirm the validity of the 2-ΔΔCT method.   
As described in 4.1.4.1, both genes were amplified in triplicate from serially 
diluted control cDNA, and the ΔCT values (CT,SMAD7 – CT,GUSB) were plotted 
against the logarithm of the concentration.  The slope of the linear regression 
line was determined to be approximately -0.04, the absolute value of which 
was sufficiently close to zero to assume that the efficiency of amplification of 
the two genes was equal, and hence that the 2-ΔΔCT method could be used to 
analyse the qPCR results generated using these primers.  
 
4.2.4.2 Basal SMAD7 Expression in Family Samples and Analysis Using the 
2-ΔΔCT Method 
Basal SMAD7 expression was determined in cultured fibroblasts taken from 
the two family members, which had not been stimulated with exogenous TGF-
β1.  Both GUSB and SMAD7 were amplified from RTSAD1.3 and RTSAD1.4 
cDNA in triplicate, and the crossing points and mean crossing points were 
calculated.  Expression of SMAD7 was normalised to GUSB for each 
individual, by calculating the ΔC T (CT, TGFB1 – CT,GUSB).  The ΔΔC T was 
calculated using Eq. [1a] (see 3.2.8.5), and the fold change in SMAD7 
expression, relative to the unaffected individual, was determined using Eq. [2] 
(3.1.5.3). 
 
Based on these calculations, no significant difference in normalised SMAD7 
expression was observed between RTSAD1.3 and RTSAD1.4 (p=0.22), 



















































are neither abnormally elevated nor depressed, in relation to the unaffected 






Figure 17. Normalised SMAD7 gene expression in unstimulated fibroblasts, relative to 
RTSAD1.4 (unaffected individual), evaluated using the 2-ΔΔCt method. No significant difference 
in expression was observed between the affected and unaffected individual (p = 0.22).  
 
4.2.4.3 RNA Isolation and cDNA Synthesis 
Total RNA was isolated from treated (with 500pM recombinant human TGF-
β1 for 1 hour) and untreated RTSAD1.3 and RTSAD1.4 cultured skin 
fibroblasts at passage seven to nine, and subjected to agarose gel 
electrophoresis to determine the quality and quantity of the RNA. 
 
The 18 and 28S rRNA bands could clearly be seen in all samples, at a 
fluorescent intensity ratio of 2:1, and since no smearing was present, the RNA 
was deemed to be intact (Fig. 18).  Although the fluorescent intensity of the 
bands under UV light indicated a low yield after extraction (particularly when 
compared to the bands visible in Fig. 5), sufficient RNA was present to 













Figure 18. Total RNA extracted from treated and untreated RTSAD1.3 and RTSAD1.4 skin 
fibroblasts, electrophoresed on a 1% agarose (0.5µg/ml Ethidium Bromide) gel to determine 
integrity.  The positions of the 28S and 18S rRNA bands are indicated with arrows. 1: Gene 
RulerTM 100bp DNA Ladder Plus Molecular Weight Marker Improved (Fermentas), 2 to 4: 
RNA isolated from RTSAD1.3 fibroblasts treated with 500pM TGF-β1, 5 to 7: RNA isolated 
from untreated RTSAD1.3 fibroblasts, 8 to 10: RNA isolated from RTSAD1.4 fibroblasts 
treated with 500pM TGF-β1. 
 
To detect possible genomic DNA contamination in the cDNA samples, after 
isolation and reverse transcription, PCR amplification was performed on a 
sample of RTSAD1.4 cDNA, using primers complementary to the intronic 
regions flanking exon 3 of TGFB1.  Amplification was anticipated only in the 
presence of genomic DNA, since cDNA contains no introns.  A sample of 
RTSAD1.4 genomic DNA was included as a positive control. 
 
As predicted, amplification of exon 3 took place when genomic DNA was used 
as a template.  In the PCR containing cDNA, however, no product was 



































Figure 19. PCR using intronic primers, designed to amplify exon 3 of TGFB1, to determine 
the presence of genomic DNA contamination. The size of a reference band in the molecular 
weight marker is shown. 1: Gene RulerTM 100bp DNA Ladder Plus Molecular Weight Marker 
Improved (Fermentas), 2: DNA-free water control, 3: RTSAD1.4 genomic DNA positive 
control, 4: RTSAD1.4 cDNA. 
 
4.2.4.4 TGF-β1-Inducible SMAD7 Expression in Family Samples and Analysis 
Using the 2-ΔΔCT Method 
The effect of TGF-β1 on SMAD7 gene expression was examined by means of 
qPCR, using cDNA synthesised from RNA isolated from treated and untreated 
RTSAD1.3 and RTSAD1.4 fibroblasts as a template.  The response to TGF-
β1 treatment was then compared between individuals, to determine whether 
differences in induction of this inhibitory Smad could account for the observed 
phenotype. 
 
Both GUSB and SMAD7 were amplified from treated and untreated 
RTSAD1.3 and RTSAD1.4 cDNA samples in duplicate, and the crossing 
points and mean crossing points were calculated.  The expression of SMAD7 
was normalised to GUSB, by calculating the ΔC T (CT, TGFB1 – CT,GUSB).  For 
each individual, the ΔΔCT was calculated using Eq. [1b] {ΔΔCT = (CT, SMAD7 – 
CT, GUSB)treated – (CT, SMAD7 – CT, GUSB)untreated}, and the fold change in SMAD7 
expression in response to treatment was determined using Eq. [2] (3.1.5.3). 
 
Based on these results, it was evident that treatment with 500pM TGF-β1 for 
1 hour caused a significant upregulation of SMAD7 mRNA expression in both 
RTSAD1.3 (p=0.0002) and RTSAD1.4 (p=0.005) fibroblasts, resulting in a 
              
                

















































two-fold increase in expression relative to the basal level of transcription of 
the gene.  However, when comparing the response to TGF-β1 treatment 
between individuals, no significant difference was observed (p=0.88).  Thus it 
appears that fibroblasts from both the affected and the unaffected individual 
are equally capable of SMAD7 upregulation in response to TGF-β1 signalling 



















Figure 20.  Fold change in SMAD7 expression in response to treatment with 500pM TGF-β1 
for 1 hour, relative to the untreated sample (-) for each individual.  A significant two-fold 
upregulation of SMAD7 transcription was observed in both RTSAD1.3 and RTSAD1.4 
(p=0.0002 and p=0.005, respectively), however this TGF-β1-inducible response did not differ 
between individuals (p=0.88). 
 
4.2.4.5 Determining Specificity of qPCR 
To determine the specificity of each of the SMAD7 qPCRs, melting curve 
analysis was performed on the LightCycler (Roche Diagnostics). For each 
primer pair (SMAD7 or the reference gene, GUSB), a single peak was 
generated, with a fragment-specific melting temperature of around 80°C, in 










the cDNA-containing samples.  This indicated the presence of a single, 
specifically amplified fragment.  A smaller peak, at approximately 75°C, was 
observed in some of the No-Template controls (NTCs), suggesting that primer 
dimerisation occurred only in the absence of template cDNA (data not shown). 
 
Results of the melting curve were confirmed by subjecting representative 
samples (one replicate per individual per primer) to agarose gel 
electrophoresis (Fig. 21).  A single band of the desired size was observed in 
all template-containing reaction tubes, demonstrating specific amplification of 

















Figure 21. Products of qPCR with SMAD7 primers, following electrophoresis on a 1% 
agarose (0.5µg/ml ethidium bromide) gel to determine specificity of amplification.  The size of 
a reference band in the molecular weight marker is shown. 1: Gene RulerTM 100bp DNA 
Ladder Plus Molecular Weight Marker Improved (Fermentas), 2 to 5: Products of qPCR from 
template-containing reaction vessels, 6: No template control.   
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The autosomal dominant fibrotic disorder described by Khumalo et al. (2006), 
characterised by poikiloderma, tendon contractures and progressive 
pulmonary fibrosis, was accorded novel status based on its unique phenotype 
and mode of inheritance, when compared to other related disorders (Khumalo 
et al. 2006).  As the biological basis of the disease remained unknown, the 
molecular characterisation of this disorder began with the identification of 
genes and/or proteins which could be responsible for the observed 
phenotype. 
 
A candidate gene approach was adopted to prioritise genes for investigation, 
since the small number of individuals available for study prevented the use of 
statistically-based methods, such as genome-wide analyses (McCarthy et al. 
2003; Ott 1991).  Based on the prominence of fibrosis in affected individuals, 
genes encoding proteins with a proven role in ECM deposition and 
fibrogenesis were chosen as candidates.  These included TGFB1, which 
encodes the profibrotic cytokine TGF-β1; and several components of the 
Smad pathway, namely Smads 2, 3 and 7, which regulate the expression of 
ECM proteins in response to TGF-β1 signalling (Clouthier et al. 1997; Kavsak 
et al. 2000; Nakao et al. 1997b; Zhang et al. 1996).  Mutations in each of 
these candidates have been previously shown to contribute to the 
development of fibrotic disease (Arany et al. 2006; Blobe et al. 2000; Clouthier 
et al. 1997; Nakao et al. 2002).  The aim of this investigation was thus to 
determine the role of TGFB1 and the abovementioned Smad proteins in the 
molecular basis of this novel disorder. 
 
Since the manifestations of this novel familial disorder are thought to be, at 
least in part, a consequence of excessive fibrosis, it was anticipated that 
disease-causing defects in TGFB1 should lead to overexpression, or 
constitutive activity, of its profibrotic protein product (Dong et al. 2002; 
Khumalo et al. 2006).  Thus, mutations were anticipated to primarily affect the 
signal sequence (disrupting trafficking and processing of the protein through 












Associated Peptide, resulting in dysregulation of activity of the TGF-β1 protein 
(Annes et al. 2003; Janssens et al. 2000; Munger et al. 1999).   
  
Previous research performed on this family had focused on the confirmation 
of TGFB1 as a candidate gene using linkage-based exclusion mapping (Ott 
1991), and on mutation screening, by means of direct sequencing of the 
exons of TGFB1 in genomic DNA of an affected and an unaffected family 
member.  Based on these results, TGFB1 could not be excluded as a 
candidate.  However, the single nucleotide polymorphisms identified during 
mutation screening were deemed not to account for the phenotype observed 
(Hartmann 2006). 
 
In this study, therefore, the investigation of TGFB1 was expanded to examine 
the length and sequence of the transcript, since whole-exon deletions, 
produced as a result of aberrant splicing, could not be detected using the 
original method of sequencing single exons at a time.   The length of the 
TGFB1 transcript in skin fibroblasts from RTSAD1.3 and RTSAD1.4 was 
determined by PCR amplification and agarose gel electrophoresis, in order to 
ascertain the presence of large-scale deletions.  The lengths of the PCR 
products generated for each individual, determined by comparison to the 
molecular weight marker, appeared sufficiently close to the predicted lengths 
based on the NCBI reference sequence (www.ncbi.nlm.nih.gov) to rule out the 
possibility of whole-exon deletions.  Agarose gel electrophoresis was selected 
as a means of analysis because of its greater range of separation, when 
compared to polyacrylamide gel electrophoresis, allowing detection of large 
variations in fragment length (0.5 to 7kb for 1% agarose) (Sambrook et al. 
1989). However in comparison to polyacrylamide, the resolving power of 
agarose is limited, preventing accurate detection of deletions of the smaller 
exons (Sambrook et al. 1989).  For this reason, the results of electrophoresis 
were confirmed by direct sequencing of the TGFB1 cDNA. 
 
It should be noted that although five members of the family had been 
diagnosed with the disease, the decision was taken to use only two 











unaffected mother, RTSAD1.4, who served as a negative control.  RTSAD1.3 
was used as a representative of the affected offspring, in the interests of 
efficiency and economy, since this individual could most readily be contacted 
for the donation of blood and skin biopsies (RTSAD1.1 being deceased, and 
RTSAD1.2 having made herself unavailable for further study).  It was 
assumed that disease-causing variants would be present in all affected 
individuals, and thus it was not necessary to screen RTSAD1.1 or RTSAD1.2 
until such a variant had been identified. 
 
Alignment of the TGFB1 transcript sequences generated for both RTSAD1.3 
and RTSAD1.4 with the NCBI reference sequence confirmed that all splice 
junctions were intact, and that the TGFB1 mRNA had been correctly 
processed in both individuals.  Thus it was concluded that aberrant splicing of 
TGFB1 could not account for the symptoms observed. 
 
Although no whole-exon deletions were observed in the TGFB1 cDNA for 
either individual, two single nucleotide polymorphisms (SNPs) were identified 
in the transcript, during the course of sequencing.  Both of these were located 
in the signal sequence (at codons 10 and 25) and have been extensively 
described in the literature. 
 
The first, a T→C substitution located in exon 1 of the transcript, was found to 
be present in the heterozygous (T/C) state in RTSAD1.3, and in the 
homozygous state in RTSAD1.4 (C/C), and was identified as the c.+29T>C 
SNP (rs1982073) M(numbered relative to the translation start site).  This 
nonsynonymous C to T substitution results in an amino acid change from 
Leucine to Proline at codon 10, in the signal sequence of the TGF-β1 
prepropeptide (Awad et al. 1998; Dunning et al. 2003).   
 
The signal sequence of a protein is a stretch of 15 to 25 amino acids 
comprised of three regions: a short N-terminal made up of positively charged 
residues, a central hydrophobic core (8 to 12 residues long) and a polar 
region, which defines the cleavage site.  The hydrophobic core, which adopts 











and ER (Awad et al. 1998).  The replacement of Leucine (encoded by the T 
variant at this SNP) with Proline (encoded by the C variant) has been 
demonstrated to cause an increase in TGFB1 transcription and translation 
(Suthanthiran et al. 2000; Yamada et al. 1998), leading to a 2.8 fold increase 
in circulating TGF-β1 levels (Dunning et al. 2003; Shin et al. 2005).   
 
The elevation of TGF-β1 expression associated with Pro10 is postulated to be 
a result of altered protein export across the ER.  The cyclical structure of 
Proline may alter the alpha-helical proportions of the signal sequence 
backbone, in contrast to the aliphatic Leucine side chain, which favours the 
formation of alpha helices (Crilly et al. 2002).  This structural alteration may, in 
turn, influence protein secretion and, since TGF-β1 is capable of regulating its 
own transcription via AP-1 sites within its promoter region, retained TGF-β1 
may upregulate its own expression by means of intracrine signalling 
(Suthanthiran et al. 2000). 
 
Increased levels of TGF-β1, corresponding to either a C/C or T/C genotype, 
have been associated with a number of disease phenotypes. Crilly et al. 
(2002) found that significant numbers of systemic sclerosis sufferers were 
heterozygous (T/C) at codon 10 (p<0.0001), while Xaubet et al. (2003) 
demonstrated a correlation between Pro10 and rapid deterioration in patients 
with Idiopathic Pulmonary Fibrosis (p=0.002). 
 
Thus it was anticipated that individuals showing symptoms of the novel 
disorder in this study, characterised by excessive fibrosis, particularly of the 
lungs and skin, should carry a Pro10 variant, indicative of increased expression 
of profibrotic TGF-β1.  While RTSAD1.3, as a T/C heterozygote, did indeed 
carry one allele coding for Proline at this position, the unaffected mother, 
RTSAD1.4, was homozygous C/C (i.e. Pro/Pro) at the equivalent position.  
This appears counterintuitive, particularly since a dose effect has been 
demonstrated for this codon, indicating that C/C individuals produce higher 
levels of TGF-β1 than heterozygotes, or T/T homozygotes (Yamada et al. 











However, the role of this SNP in fibrotic disease remains controversial.  While 
most studies agree on the role of the “C” (Pro) allele in the elevation of TGF-
β1 expression, some research groups have found the opposite (Mattey et al. 
2005).  Among them are Awad and colleagues, who reported an increased 
frequency of the Leu20 variant in cystic fibrosis patients with lung fibrosis 
(p<0.01), a fact which they hypothesise to be due to increased expression of 
TGF-β1 in individuals with the T/T genotype (Awad et al. 1998).    
 
Additionally, the relatively high allele frequencies recorded for this SNP in 
Caucasians (C=0.549, T=0.451) on the NCBI SNP database 
(www.ncbi.nlm.nih.gov) indicate that neither the T nor the C allele at this 
codon alone could account for the symptoms and inheritance pattern of this 
rare, novel disease.  Together with the conflicting reports regarding the effect 
of the c.+29T>C variant on TGF-β1 expression levels, these facts suggest 
that this is a common polymorphism that is unlikely to play a role in the 
pathogenesis of the disease under study. 
 
The second SNP, identified as the c.+74G>C polymorphism, was found in the 
homozygous (G/G) state in the affected individual, and in the heterozygous 
(G/C) state in his unaffected mother.  This variant is also located in the signal 
sequence of TGF-β1, at codon 25, proximal to the cleavage site at codon 29 
(Carturan et al. 2004).  The change from a G to a C at this position 
corresponds to an amino acid change from an Arginine to a Proline.  This 
results in the exchange of the large, polar side chain of Arginine for the small 
non-polar Proline side chain, which has been postulated to either disrupt the 
hydrophobic core of the signal sequence, or to affect the adjacent cleavage 
site (Stoll et al. 2004; Awad et al. 1998; Cambien et al. 1996).  Protein 
function may also be altered, due to a predicted change in the folding of the 
amino acid chain (Awad et al. 1998). 
 
The c.+74 G/G (Arg/Arg) genotype has been shown to result in increased 
production of TGF-β1 by stimulated lymphocytes when compared either to 
heterozygotes, or to C/C homozygotes (Awad et al. 1998).  Thus it follows that 











TGF-β1, has been significantly associated with systemic sclerosis (p=0.027) 
(Crilly et al. 2002) and pretransplant fibrotic lung pathology (p<0.02) (Awad et 
al. 1998).  Notably, the combination of an Arg/Arg genotype at codon 25 and a 
codon 10 Leucine allele has been identified as a marker for poor post-
transplant prognosis due to fibrosis (Awad et al. 1998). 
 
The codon 25 genotypes of RTSAD1.3 (G/G) and RTSAD1.4 (G/C) therefore 
fit the hypothesised model of higher levels of TGF-β1 (leading to increased 
fibrogenesis) in individuals affected by the novel disorder, when compared to 
unaffected individuals.  Additionally, the strong association of the Arg25 variant 
with pulmonary fibrosis, and its proposed combinatorial effect with Leu10 to 
bring about the fibrotic phenotype, raises the possibility that these variants, 
acting in combination with others, may play a role in the molecular basis of 
this disease.  However, such considerations must be treated with caution, 
since the high frequency of the G allele in Caucasians (0.887) 
(www.ncbi.nlm.nih.gov) implies that this variant is common in the background 
population and hence cannot be solely responsible for the observed fibrotic 
phenotype and inheritance pattern of this disorder. 
 
In addition to the length and sequence of the transcript, TGFB1 mRNA 
expression levels were examined, in fibroblasts taken from the affected and 
unaffected family members, by means of real-time quantitative PCR (qPCR).  
It was anticipated that quantification of the transcript would provide 
information about the regulation of the gene, while eliminating the need to 
sequence the extended regulatory region, which comprises more than 2.6kb 
of sequence upstream of the transcription start site (Shah et al. 2006).  
Alterations in various components of this regulatory region have previously 
been shown to result in constitutive or abnormally elevated expression of the 
gene, resulting in the development of fibrosis (Shah et al. 2006; Shin et al. 
2005; Silverman et al. 2004; Grainger et al. 1999).  Additionally, it was 
expected that qPCR analysis of the transcript would clarify the effect of the 












Analysis of the results of qPCR was performed by means of relative 
quantification, using the 2-ΔΔCT method described by Livak and Schmittgen 
(2001).  Relative quantification describes the change in expression of a target 
gene (TGFB1) in an experimental group, relative to a reference group.  An 
endogenous reference gene is included, to normalise for the amount of RNA 
added to the initial reverse transcription reactions (Livak and Schmittgen 
2001).  In this case, the affected individual was treated as the experimental 
group, while the unaffected individual served as the reference.  The 
housekeeping gene GUSB was chosen as an endogenous reference gene, 
once the efficiencies of amplification of both genes had been calculated, and 
found to be approximately equal.   
 
The results of the qPCR experiment showed no significant difference in 
TGFB1 expression between RTSAD1.3 and RTSAD1.4 (p=0.43).  Thus, it 
could be inferred that overexpression of profibrotic TGFB1 was not 
responsible for the disease phenotype observed in the affected individual. 
 
This finding was significant, since it implied that the disease-causing defect 
was not present in either the extended 5’ regulatory region of TGFB1, or in 
any other genetic component regulating the expression of the gene.  
Elimination of TGFB1 as a candidate was an important step in the 
characterisation of this fibrotic disease, since overexpression of this gene, and 
its protein product, are widely regarded as central to the development of 
fibrosis in numerous diseases, affecting most tissues of the body (Verrecchia 
et al. 2007; Shah et al. 2006; Bartram and Speer 2004; Nakao et al. 2002; 
Blobe et al. 2000; Awad et al. 1998).  
 
Additionally, the results of qPCR indicate that neither of the signal sequence 
polymorphisms described above significantly modifies the expression of the 
TGFB1 transcript in either individual.  The p-values calculated for this 
experiment must however be treated with caution, since the small sample size 
used makes detection of small variations in expression difficult (Whitley and 











cannot be attributed either to structural defects in the TGFB1 transcript, or to 
aberrant regulation of its expression. 
 
The focus of the investigation therefore shifted to the examination of various 
Smad proteins, which had been identified as candidate genes based on their 
role in the transduction of TGF-β1 signalling and the regulation of genes 
involved in fibre deposition (Dong et al. 2002; Nakao et al. 2002; Varga et al. 
2002; Venkatesan et al. 2004).  The receptor-regulated Smads, namely 
Smad2 and Smad3, are phosphorylated by ligand-bound TGF-β1 receptors, 
resulting in a conformational change allowing recruitment of the common 
Smad, Smad4.  This complex is then translocated to the nucleus, where it 
regulates the expression of various fibrogenic target genes in response to 
TGF-β1 signalling (Arai et al. 1998; Chen et al. 2002; Mori et al. 2000; Nakao 
et al. 1997b; Tsukazaki et al. 1998; Zawel et al. 1998; Zhang et al. 1996).   
 
In this study, expression and phosphorylation of the R-Smads were quantified 
in TGF-β1-stimulated and unstimulated fibroblasts from both individuals.  
Since the excessive fibrosis observed in affected individuals is thought to 
result from hyperinduction of the profibrotic signalling cascade, the hypothesis 
was formulated that overexpression or constitutive phosphorylation of the R-
Smads could account for the development of the disease (Dong et al. 2002).  
In structural terms, this could result from a mutation in the MH1 domain, 
affecting its ability to inhibit the receptor-binding and oligomerisation activity of 
the MH2 domain (Lo et al. 1998; Lo et al. 1999; Massagué 1998; Ross et al. 
2007; ten Dijke et al. 2000) and thus producing an active protein conformation 
in the absence of a stimulus.  Alternatively, mutations producing constitutively-
active forms of either the C-tail (containing the SS[X]S motif phosphorylated 
by TGF-β receptors) or the linker region (phosphorylated by other Smad 
pathway regulators, such as MAP kinases) could result in ligand-independent 
signalling (Lo et al. 1998; Lo et al. 1999; ten Dijke et al. 2000).  Finally, 
inactivation of the SARA complex, responsible for subcellular localisation of 
the receptor-regulated Smads in the absence of signal (Chacko et al. 2001; 












However, when the expression of Smad2/3 was examined, no significant 
difference was observed between fibroblasts which had been treated with 
TGF-β1, and those that had not, for each of the family members (RTSAD1.3 
or RTSAD1.4), and their age- and sex-matched controls (Control 2 and 
Control 1, respectively).  Thus it would appear that stimulation with TGF-β1 
has no effect on the expression of Smad2/3.  This is to be expected since, 
under normal physiological conditions, the induction of the Smad signalling 
cascade by TGF-β1 results in a change in the phosphorylation state and 
subcellular compartmentalisation of the R-Smads, but does not affect their 
expression (Mori et al. 2000; Varga et al. 2002). 
 
Of greater interest, therefore, were the inter-individual differences in Smad2/3 
expression, since previous research has demonstrated an association 
between elevated Smad3 expression and the development of fibrosis in the 
skin lesions of systemic sclerosis patients (Dong et al. 2002).  In order to 
compare R-Smad expression between individuals, the ratio of 
treated:untreated band densities was calculated for each individual, and 
comparisons were then made between the two family members, and between 
each family member and his/her matched control.  Again, no significant 
difference was observed between any of the individuals compared, 
suggesting that Smad2/3 is found at normal levels in the skin fibroblasts of 
affected individuals, and hence that overexpression of this profibrotic 
signalling molecule does not play a role in the development of the disorder. 
 
It should however be noted that several technical errors could have influenced 
the results of this experiment.  For instance, during cell culture, the speed and 
homogeneity of growth varied between cell lines and between replicates, 
resulting in differing degrees of confluence at the time of treatment with TGF-
β1.  This could have affected the concentration of TGF-β1 relative to cell 
count, the level of signalling (depending on the proximity of the cells), and the 
concentration of total protein present in the cell lysate after extraction.  This 
could explain the discrepancy in band density between Control 1 and the 
other three cell lines, observed in Figure 15.  Several measures were 











extractions in triplicate and the western blots in duplicate, probing for the 
housekeeping protein Actin (as a loading control) and allowing the cells to 
grow to uniform (85%) confluence whenever possible.  Normalisation of 
treated to untreated samples, prior to inter-individual comparisons, also 
minimised the discrepancies resulting from different speeds of growth 
between cell lines.  
 
There are two further considerations which must be made when interpreting 
these results.  Firstly, it has been demonstrated that the development of 
fibrosis may result from a failure to downregulate Smad3, in response to 
prolonged TGF-β1 signalling (Dong et al. 2002).  Thus, although no difference 
in Smad2/3 expression was observed in this experiment, after one hour of 
treatment, results may differ as the duration of TGF-β1 exposure is increased.  
A time-course experiment is therefore proposed to more accurately determine 
the affected individual’s ability to regulate Smad2/3. 
 
Secondly, the role of the receptor-regulated Smads in perpetuating TGF-β1 
signalling is strongly linked to their subcellular localisation.  In scleroderma 
patients, for instance, excessive nuclear accumulation of R- and Co-Smads 
has been linked to the development of fibrosis (Dong et al. 2002).  
Immunohistochemical analysis is therefore recommended to determine the 
subcellular location of R- and Co-Smads in the fibrotic tissue of individuals 
affected with this novel disease. 
 
R-Smad phosphorylation, indicative of the level of TGF-β1/Smad signalling, 
was quantified in fibroblasts of the affected and unaffected individual, as well 
as their matched controls, by means of western blot.  Whole cell lysates from 
treated (with TGF-β1) and untreated fibroblasts of each individual were 
probed for phosphorylated Smad3, giving an indication of the basal and TGF-
β1-inducible signalling response.  It has been previously reported that 
constitutive Smad2 or Smad3 phosphorylation, indicative of hyperactivity of 
the Smad signalling cascade in the absence of a stimulus, can lead to the 
development of pathological fibrosis (Venkatesan et al. 2004).  Similarly, an 











hyperactivity of the pathway and hence, a greater propensity for the 
accumulation of fibrous deposits (Dong et al. 2002). 
 
Based on this hypothesis, it was anticipated that phosphorylated Smad3 
should be observed in the whole cell lysates of both the treated and untreated 
fibroblasts of the affected individual, compared to the unaffected controls, in 
which Smad3 phosphorylation should only be detected in response to TGF-β1 
treatment.  Alternatively, the levels of Smad3 phosphorylation in stimulated 
fibroblasts were expected to be elevated in the affected individual, relative to 
the control individuals.   
 
However, this was not the case.  In the whole cell lysates of untreated 
fibroblasts of all four individuals, phosphorylated Smad3 was virtually absent, 
while treatment with TGF-β1 resulted in marked upregulation of signalling, 
yielding a clearly visible band corresponding to the phosphorylated R-Smad.  
When comparing differences in response to TGF-β1 treatment between 
individuals, no significant difference in the treated:untreated band density ratio 
was observed between any of the individuals.  These results indicated that 
phosphorylation of Smad3 in the affected individual (RTSAD1.3) was neither 
constitutive, nor abnormally elevated, in comparison to phenotypically normal 
individuals and appeared to be physiologically responsive to ligand 
stimulation.  Thus it was concluded that aberrant phosphorylation of the 
receptor-regulated Smad proteins could not account for the excessive fibrosis 
characteristic of this novel disorder. 
 
Again, there were several limitations which should be taken into account when 
interpreting the results of this experiment.  As previously mentioned, inter-
individual variations in speed and homogeneity of cell growth may have 
affected the response of different cell lines to treatment with TGF-β1.  
However, as for western blot detection of Smad2/3, triplicate isolation, 
duplicate detection and the inclusion of an anti-Actin probe as a loading 












However, an additional difficulty was encountered during western blot 
optimisation using the anti-phosphoSmad3 primary antibody.  Due to the 
relatively low abundance of the phosphorylated protein in the whole cell lysate 
and the high selectivity of the monoclonal primary antibody used in detection, 
a secondary antibody dilution of 1:1000 (2-fold higher than the manufacturer’s 
recommended dilution) in combination with a super-sensitive 
chemiluminescent substrate solution was required to detect the target protein.  
This resulted in high background signal, caused by non-specific binding of the 
secondary antibody.  Various optimisation steps were therefore employed in 
an attempt to increase the intensity of the phospho-protein band and eliminate 
background signal, including increasing the concentration of TGF-β1 used in 
treatment {to 800pM, compared with the 500pM recommended by Dong et al. 
(2002)} and increasing the frequency, duration and volume of washes.  
However, reduced background could not be achieved without compromising 
detection of the phosphoSmad3 band.  The results presented in Figure 16 
therefore represent the best signal:noise ratio obtained with this combination 
of antibodies.  In order to confirm these results, it is recommended that the 
reaction be further optimised (by adjusting various parameters such as 
antibody dilutions, washes or blocking reagents, or by the inclusion of an 
immunoprecipitation step to concentrate the target protein) to enable more 
accurate discrimination between specific bands and non-specific signal, 
thereby improving analysis. 
 
The final component of the Smad pathway investigated in this study was the 
gene encoding the inhibitory Smad, SMAD7.  In response to TGF-β1 
signalling, SMAD7 transcription is rapidly induced by activated R-
Smad/Smad4 heteromers which have been translocated to the nucleus (Mori 
et al. 2000; Nakao et al. 1997a; Nakao et al. 2002; Takagawa et al. 2003).  
This initiates a negative feedback loop, in which the Smad7 protein 
downregulates TGF-β1 signalling by either binding to activated TGF-β1 
receptors directly, preventing their association with R-Smads (Kloos et al. 
2002; Nakao et al. 1997a), or by recruiting an E3 ubiquitin-protein ligase to 












Several studies have shown that the expression level of SMAD7 influences 
cellular responsiveness to TGF-β1 (Nakao et al. 1997a; Venkatesan et al. 
2004).  Specifically, decreased expression of SMAD7, resulting in failure to 
terminate Smad signalling in response to TGF-β1, has been shown to be 
associated with the development of fibrosis in the skin and lungs of 
bleomycin-treated mice (Takagawa et al. 2003; Venkatesan et al. 2004) and 
human systemic sclerosis patients (Dong et al. 2002).  Thus it was expected 
that basal SMAD7 mRNA expression would be lower in affected individuals, 
when compared to unaffected individuals, and that induction of SMAD7 
transcription in affected individuals would be depressed (Dong et al. 2002). 
 
To test this hypothesis, basal and TGF-β1-inducible SMAD7 mRNA 
expression was evaluated in skin fibroblasts of an affected and an unaffected 
family member by means of real-time qPCR.  Analysis was performed using 
the 2-ΔΔCT method described previously (Livak and Schmittgen 2001), 
incorporating GUSB as an internal reference gene.  Basal SMAD7 levels were 
presented as the fold change in normalised expression relative to the 
expression of the transcript in the unaffected individual.  Based on these 
results, it was concluded that SMAD7 transcription did not differ significantly 
between individuals, in fibroblasts which had not been stimulated with 
exogenous TGF-β1.    
 
For each individual, a statistically significant two-fold increase in SMAD7 
expression, relative to the basal level, was observed in response to treatment 
with recombinant TGF-β1 for 1 hour.  However, when the TGF-β1-inducible 
response was compared between individuals, no significant difference was 
found.  This indicates that the negative regulatory mechanism controlling 
profibrotic signalling in response to TGF-β1 is intact in affected individuals. 
 
It must be noted, however, that the observed two-fold induction of SMAD7 
expression in response to stimulation with TGF-β1 differs substantially from 
previous results reported by similar studies.  Dong and colleagues, whose 
2002 investigation highlighted the role of depressed SMAD7 expression in 











after 1 hour of TGF-β1 treatment, in normal and systemic sclerosis cultured 
fibroblasts, respectively.  Since both the affected and unaffected individual in 
this study show a markedly lower induction of expression, this result is 
unlikely to be related to the pathogenesis of the disease.  It is possible that 
the difficulties encountered in cell culture described above may have 
influenced the cells’ response to TGF-β1.  Additionally, the small surface area 
of the dishes used to culture the fibroblasts limited the total cell count, leading 
to a decrease in quantity and quality of RNA after extraction and hence, to a 
decrease in quality and quantity of template cDNA (necessitating the use of a 
much higher template cDNA concentration for qPCR than the generally 
recommended 100ng/µl).  A combination of these factors may therefore have 
resulted in relatively lower TGF-β1-inducible SMAD7 expression levels in the 
family members investigated in this study.  Nevertheless, the fact that TGF-β1 
treatment consistently resulted in a 2-fold induction of expression between 
replicates and between individuals suggests that although these results differ 
from previous reports, reliable conclusions can nevertheless be drawn from 
the data. 
 
Taken together with the results of the Smad2/3 expression and 
phosphorylation experiments, it appears that excessive Smad signalling is 
unlikely to account for the development of fibrosis observed in affected 
individuals.  Although several components of the TGF-β-responsive signalling 
cascade (namely the TGF-β-receptors I and II, and the co-Smad, Smad4) 
were not investigated in this study, it was assumed that an investigation of R-
Smad phosphorylation would serve as an indicator of aberrations in upstream 
genes/proteins resulting in excessive signalling.   
 
It therefore seems reasonable to conclude that defects in the Smad pathway 
are not responsible for the disease described by Khumalo et al. (2006).  This 
is in contrast to scleroderma, a related disorder described in 2.1.2.4, in which 
decreased basal and TGF-β1-inducible SMAD7 expression, in combination 
with elevated Smad3 expression, results in unchecked activation of the TGF-
β1 autocrine signalling loop, a factor identified as important in the 










genetic basis of the disease under investigation, and highlights the need for a 













In this study, various components of the TGF-β/Smad signalling cascade were 
investigated at the transcriptional, translational and post-translational levels, 
to determine their role in the molecular basis of a novel, autosomal dominant 
fibrotic disease.  These included TGFB1, Smad2, Smad3 and SMAD7. 
 
Examination of the length and sequence of the TGFB1 transcript, encoding 
the profibrotic cytokine TGF-β1, revealed no large-scale deletions, indicating 
correct post-transcriptional processing.  Although two SNPs were identified 
during sequencing, both of which had previously been reported to affect the 
expression of TGF-β1, the high frequencies of these variants in the 
background population suggest that they do not account for the rare 
phenotype observed.  Additionally, no difference was found when comparing 
TGFB1 expression in the skin fibroblasts of an affected and an unaffected 
family member, indicating that aberrant expression and/or processing of 
TGFB1 does not appear to account for the symptoms of the disease. 
 
With respect to Smad2/3 expression and phosphorylation, no difference was 
observed between the cultured fibroblasts of affected and unaffected family 
members, or between family members and their matched controls, following 
treatment with TGF-β1.  This indicated that the TGF-β1 signalling response 
was neither constitutively active, nor hyperresponsive, in the affected 
individual studied.  Finally, basal and TGF-β1 inducible SMAD7 mRNA 
expression was found not to differ between skin fibroblasts of the affected and 
unaffected family member, suggesting that the observed symptoms could not 
be attributed to prolonged activity of the Smad pathway in the absence of a 
negative regulator. 
 
The combination of these results, obtained from different levels of regulation 
of the TGF-β1/Smad pathway, suggest that dysregulation of this signalling 
cascade is not responsible for the development of fibrosis in the novel 












related disorders.  Continued research is therefore required in order to identify 











7. Future Work 
Further investigation into the molecular basis of this disease should follow one 
of two approaches, depending on the availability of biological material from 
the extended family.  In the absence of additional blood and/or tissue 
samples, it seems prudent to continue the investigation using the candidate 
gene approach.  Results of this study strongly suggest that the TGF-β1/Smad 
signalling pathway does not play a causal role in the development of fibrosis 
in affected family members.  Thus, it seems logical to extend the search to 
include other likely candidates.  These may include genes whose 
physiological function matches the proposed disease mechanism (that is, 
genes involved in the deposition, regulation of expression or degradation of 
extracellular matrix components), or those genes previously implicated in 
related disorders, such as Rothmund-Thomson syndrome. 
 
Should biological material from additional affected family members become 
available, however, it may be feasible to employ whole-genome techniques, 
such as comparative genomic hybridisation (CGH) or expression arrays. 
Since these techniques enable the detection of sequence aberrations ranging 
from single nucleotide polymorphisms to large scale deletions across the 
entire genome, it is likely that mutations would be identified at a far more rapid 
rate using these methods, compared to the laborious, hypothesis-driven 
candidate gene approach. 
 
In addition, future work should entail the confirmation and improvement of 
results obtained in this study.  Due to the high degree of clinical heterogeneity 
observed in this disorder, it is recommended that the experiments be 
expanded to include the remaining affected individuals if possible, to confirm 
the absence of disease-causing mutations in the genes/proteins studied.   
 
The Smad2/3 western blot results should be expanded to include a time-
course experiment, in which expression of the R-Smads is monitored 
following increasing durations of TGF-β1 treatment, to determine the ability of 












Additionally, immunohistochemical analysis should be performed on fibrotic 
lesions from the affected individual, if possible, to determine the subcellular 
localisation of the R- and Co-Smads before and after treatment with TGF-β1.  
Further work is also needed to improve the result of the anti-phosphoSmad3 
western blot, in order to obtain an optimal signal:noise ratio, allowing the 
experiment to be repeated and analysed reliably.  This may involve the 
alteration of western blot parameters (such as antibody concentrations, wash 
times and volumes), as well as optimisation of cell culture conditions. 
 
However, since no pathogenic defect has been identified in the TGF-β1/Smad 
cascade thus far, research in the future is likely to extend beyond this 
pathway, to the identification of new candidates, or to the whole-genome 
techniques described above.  Additionally, a larger-scale morphological 
approach may be taken, involving the examination of cultured fibroblast 
morphology and behaviour using fluorescent and/or electron microscopy.  
This is likely to reveal details such as rate of growth, cell mortality and 
organelle morphology, all of which will shed light on the cellular effects of this 
disease, and aid in the identification of candidate genes for study. 
 
Finally, it has been postulated that the syndromic nature of this disease, 
characterised by a severe systemic phenotype, points to the possible 
involvement of DNA instability, a phenomenon observed in other related 
disorders, such as RTS.  This may also be investigated, using cytogenetic 
techniques. 
 
It is hoped that the recruitment of additional family members to the study will 
enable the use of more sophisticated methods of mutation screening.  Until 
then, however, it is likely that the future of research into the molecular basis of 
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Appendix A: Buffers and Reagents for Agarose 
Gel Electrophoresis 
10x TBE 
108g Tris (USB Corporation, Cleveland, USA) 
55g Boric Acid (Promega)  
7.4g EDTA (Merck, Darmstadt, Germany) 
Made up to final volume of 1 litre using distilled water and autoclaved. 
Diluted to working stock of 1x 
 
1% Agarose incorporating 0.5µg/ml Ethidium Bromide 
1g  Agarose LE (Roche Diagnostics) 
100ml  1X TBE 
5µl  10mg/ml Ethidium Bromide (SIGMA-ALDRICH) 
 
Loading Buffer 
0.125g (0.25% v/v)  Bromophenol Blue (Merck) 
20g (40% v/v)  Sucrose (BDH Laboratory Supplies, Poole, UK) 













Appendix B: Molecular Weight Markers 
 
B.1 Gene Ruler™ 100bp DNA Ladder Plus Improved (Fermentas) 
  












Appendix C: Annotated TGFB1 mRNA Sequence 
Indicating Position of Sequencing Primers 
    1 ccttcgcgcc ctgggccatc tccctcccac ctccctccgc ggagcagcca gacagcgagg 
   61 gccccggccg ggggcagggg ggacgccccg tccggggcac ccccccggct ctgagccgcc 
  121 cgcggggccg gcctcggccc ggagcggagg aaggagtcgc cgaggagcag cctgaggccc 
  181 cagagtctga gacgagccgc cgccgccccc gccactgcgg ggaggagggg gaggaggagc 
  241 gggaggaggg acgagctggt cgggagaaga ggaaaaaaac ttttgagact tttccgttgc 
  301 cgctgggagc cggaggcgcg gggacctctt ggcgcgacgc tgccccgcga ggaggcagga 
  361 cttggggacc ccagaccgcc tccctttgcc gccggggacg cttgctccct ccctgccccc 
  421 tacacggcgt ccctcaggcg cccccattcc ggaccagccc tcgggagtcg ccgacccggc___F  
  481 ctcccgcaaa gacttttccc cagacctcgg gcgcaccccc tgcacgccgc cttcatcccc 
  541 ggcctgtctc ctgagccccc gcgcatccta gaccctttct cctccaggag acggatctct 
  601 ctccgacctg ccacagatcc cctattcaag accacccacc ttctggtacc agatcgcgcc 
  661 catctaggtt atttccgtgg gatactgaga cacccccggt ccaagcctcc cctccaccac 
  721 tgcgcccttc tccctgagga cctcagcttt ccctcgaggc cctcctacct tttgccggga 
  781 gacccccagc ccctgcaggg gcggggcctc cccaccacac cagccctgtt cgcgctctcg___F* 
  841 gcagtgccgg ggggcgccgc ctcccccatg ccgccctccg ggctgcggct gctgccgctg 
  901 ctgctaccgc tgctgtggct actggtgctg acgcctggcc ggccggccgc gggactatcc 
  961 acctgcaaga ctatcgacat ggagctggtg aagcggaagc gcatcgaggc catccgcggc 
 1021 cagatcctgt ccaagctgcg gctcgccagc cccccgagcc agggggaggt gccgcccggc 
 1081 ccgctgcccg aggccgtgct cgccctgtac aacagcaccc gcgaccgggt ggccggggag 
 1141 agtgcagaac cggagcccga gcctgaggcc gactactacg ccaaggaggt cacccgcgtg 
 1201 ctaatggtgg aaacccacaa cgaaatctat gacaagttca agcagagtac acacagcata 
 1261 tatatgttct tcaacacatc agagctccga gaagcggtac ctgaacccgt gttgctctcc 
 1321 cgggcagagc tgcgtctgct gaggctcaag ttaaaagtgg agcagcacgt ggagctgtac 
 1381 cagaaataca gcaacaattc ctggcgatac ctcagcaacc ggctgctggc acccagcgac 
 1441 tcgccagagt ggttatcttt tgatgtcacc ggagttgtgc ggcagtggtt gagccgtgga 
 1501 ggggaaattg agggctttcg ccttagcgcc cactgctcct gtgacagcag ggataacaca 
 1561 ctgcaagtgg acatcaacgg gttcactacc ggccgccgag gtgacctggc caccattcat 
 1621 ggcatgaacc ggcctttcct gcttctcatg gccaccccgc tggagagggc ccagcatctg 
 1681 caaagctccc ggcaccgccg agccctggac accaactatt gcttcagctc cacggagaag 
 1741 aactgctgcg tgcggcagct gtacattgac ttccgcaagg acctcggctg gaagtggatc___R* 
 1801 cacgagccca agggctacca tgccaacttc tgcctcgggc cctgccccta catttggagc 
 1861 ctggacacgc agtacagcaa ggtcctggcc ctgtacaacc agcataaccc gggcgcctcg 
 1921 gcggcgccgt gctgcgtgcc gcaggcgctg gagccgctgc ccatcgtgta ctacgtgggc 
 1981 cgcaagccca aggtggagca gctgtccaac atgatcgtgc gctcctgcaa gtgcagctga___R 
 2041 ggtcccgccc cgccccgccc cgccccggca ggcccggccc caccccgccc cgcccccgct 
 2101 gccttgccca tgggggctgt atttaaggac acccgtgccc caagcccacc tggggcccca 
 2161 ttaaagatgg agagaggact gcggatctct gtgtcattgg gcgcctgcct ggggtctcca 
 2221 tccctgacgt tcccccactc ccactccctc tctctccctc tctgcctcct cctgcctgtc 
 2281 tgcactattc ctttgcccgg catcaaggca caggggacca gtggggaaca ctactgtagt 
 2341 tagatctatt tattgagcac cttgggcact gttgaagtgc cttacattaa tgaactcatt 
      cagtcaccat agcaacactc tgagatgcag ggactctgat aacacccatt ttaaaggtga  
      ggaaacaagc ccagagaggt taagggagga gttcctgccc accaggaacc tgctttagtg  
      ggggatagtg aagaagacaa taaaagatag tagttcaggc caggcggggt ggctcacgcc  
              tgt 
 
Key: Exon 1 is indicated in pink, Exon 2 in red, Exon 3 in light green, Exon 4 in blue, Exon 5 
in orange, Exon 6 in dark green and Exon 7 in grey.  Primers are underlined (F, whole 
transcript forward primer, F*, internal fragment forward primer, R, whole transcript reverse 
primer and R*, internal fragment reverse primer).  The translation start and stop codons are 
indicated in bold, while the 3’ untranslated region is designated by italics.  Numbers 











Appendix D: Manufacturer’s Protocols 
D.1 High Pure RNA Isolation Kit (Roche) 
Isolation of Total RNA from Cultured Cells (suited for 1 × 106 cells) 
1.  Resuspend cells in 200 µl PBS. 
2.  Add 400 µl Lysis/-Binding Buffer (green cap) and vortex for 15 s. 
3.  To transfer the sample to a High Pure Filter Tube: 
 • Insert one High Filter Tube in one Collection Tube. 
 • Pipet entire sample into the upper reservoir of the Filter Tube (max. 
700µl) 
4. • Insert the entire High Pure Filter Tube assembly into a standard 
tabletop centrifuge. 
 • Centrifuge the tube assembly 15 s at 8,000 × g. 
5.  After centrifugation: 
• Remove the Filter Tube from the Collection Tube, discard the 
flowthrough liquid, and again combine the Filter Tube and the used 
Collection Tube. 
6.  After re-inserting the Filter Tube: 
• Pipette per sample 90 µl DNase Incubation Buffer (white cap) into a 
sterile reaction tube, add 10 µl DNase I, mix and pipette the solution on 
the glass filter fleece in the upper reservoir of the filter tube. 
 • Incubate for 15 min at +15 to +25°C. 
7. • Add 500 µl Wash Buffer I to the upper reservoir of the Filter Tube 
assembly and centrifuge 15 s at 8,000 × g. 
 • Discard flowthrough and combine Filter Tube with the used Collection 
Tube. 
8. • Add 500 µl Wash Buffer II (blue cap) to the upper reservoir of the Filter 
Tube assembly and centrifuge 15 s at 8,000 × g. 
• Discard flowthrough and combine Filter Tube with the used Collection 
Tube.   
9. Add 200µl Wash Buffer II (blue cap) to the upper reservoir of the Filter 
Tube assembly and centrifuge for 2 min at maximum speed (approx. 
13,000 × g) to remove any residual Wash Buffer. 











10. Discard the Collection Tube and insert the Filter Tube into a clean, sterile 
1.5 ml microcentrifuge tube. 
11. To elute the RNA: 
 • Add 50 – 100 µl Elution Buffer to the upper reservoir of the Filter Tube. 
 • Centrifuge the tube assembly for 1 min at 8,000 × g. 
12.  The microcentrifuge tube now contains the eluted RNA.  Either use the 
eluted RNA directly in RT-PCR or store the eluted RNA at –80°C for later 
analysis 
 
D.2 QIAquick® Gel Extraction Kit (QIAGEN) 
1. Excise the DNA fragment from the agarose gel with a clean, sharp 
scalpel. 
2. Weigh the gel slice in a colourless tube.  Add 3 volumes of buffer QG 
to 1 volume of gel (100mg ≈ 100µl) 
3. Incubate at 50ºC for 10min (or until the gel slice has completely 
dissolved).  To help dissolve gel, mix by vortexing the tube every 2-
3min during the incubation, 
4. After the gel slice has dissolved completely, check the colour of the 
mixture is yellow (similar to Buffer QG without dissolved agarose). 
5. Add 1 gel volume of isopropanol to the sample and mix. 
6. Place a QIAquick spin column in a provided 2ml collection tube. 
7. To bind DNA, apply the sample to the QIAquick column, and centrifuge 
for 1min. 
8. Discard flow through and place QIAquick column back in the same 
collection tube. 
9. Add 0.5ml of Buffer QG to QIAquick column and centrifuge for 1 min. 
10. To wash, add 0.75ml of Buffer PE to QIAquick column and centrifuge 
for 1 min. 
11. Discard the flow through and centrifuge the QIAquick column for an 
additional 1 min at 13000rpm. 
12. Place the QIAquick column into a clean 1.5ml microcentrifuge tube. 
13. To elute DNA, add 30ml dH2O to the centre of the QIAquick membrane 











D.3 Transcriptor First Strand cDNA Synthesis Kit (Roche) 
Procedure A: cDNA Synthesis with anchored oligo(dT)18 primer  
1.  • Thaw all frozen reagents before use. 
 • Briefly centrifuge them before starting the procedure. 
• Keep all reagents on ice while setting up the reactions. 
2. In a sterile, nuclease-free, thin-walled PCR tube on ice, prepare the 
template-primer mixture for one 20 µl reaction by adding the components 
in the order listed below. 
* Always wear gloves when handling RNA. 
 
3. Optional Step: 
• Denature the template-primer mixture by heating the tube for 10 min at 
65°C in a thermal block cycler with a heated lid (to minimize evaporation). 
This step ensures denaturation of RNA secondary structures. 
• Immediately cool the tube on ice. 
4. To the tube containing the template-primer mix, add the remaining 













5.  • Mix the reagents in the tube carefully. 
* Do not vortex! 
• Centrifuge the tube briefly to collect the sample on the bottom of the 
tube. 
• Place the tube in a thermal block cycler with a heated lid (to minimize 
evaporation). 
6.  Depending on the primer used and the length of the target mRNA, 
incubate the RT reaction as described in the table below: 
 
 
7.  • Inactivate Transcriptor Reverse Transcriptase by heating to 85° for 5min. 
• Stop the reaction by placing the tube on ice. 
• At this point the reaction tube may be stored at +2 to +8°C for 1-2 hrs or 











Appendix E: Buffers and Reagents for SDS-
PAGE and Western Blot  
7.5% Resolving Gel (Laemmli Resolving Gel 29:1 or 37:5:1 Ratio) 
2.5ml       1.5M Tris-HCl pH 8.8 
2.5ml       30% Acrylamide/Bisacrylamide (SIGMA-ALDRICH) 
4.85ml     Deionised Water 
0.1ml       10% SDS 
50µl         10% Ammonium Persulfate 
5µl           TEMED (BIO-RAD) 
 
4% Stacking Gel 
0.66ml     30% Acrylamide/Bisacrylamide (SIGMA-ALDRICH) 
1.26ml     0.5M Tris-HCl pH 6.8 
3ml          Deionised Water 
50µl         10% SDS 
25µl         10% Ammonium Persulfate 
5µl           TEMED (BIO-RAD) 
 
10x Electrophoresis Running Buffer 
30.28g      Tris Base 
144.13g    Glycine 
10g           SDS 
Dissolve in 1l deionised water. 
For electrophoresis, dilute to 1x in deionised water before use. 
 
10x Transfer Buffer 
30.28g       Tris-HCl 
144.13g      Glycine 
Dissolve in 800ml deionised water. 
Before use, dilute 80ml of stock in 720ml deionised water and add 200ml 












1.5M Tris-HCl pH8.8 
28.5g         Tris-HCl 
69.05g       Tris-Base 
Dissolve in 500ml deionised water 
 
0.5M Tris-HCl pH 6.8 
38.15g       Tris-HCl 
0.95g         Tris-Base 
Dissolve in 500ml deionised water 
 
1M Tris-HCl pH 6.8 
74.86g       Tris-HCl 
3.03g         Tris-Base 
Dissolve in 500ml deionised water 
 
Tris Buffered Saline + 0.1% Tween 20 (TBST) 
6.8g           Tris-HCl 
0.82g         Tris-Base 
8.77g         NaCl 
Dissolve in deionised water, then add 
5ml             20% Tween 20 
Make up to 1l with deionised water. 
 
5x Laemmli Sample Buffer (Laemmli, 1970) 
1.25ml        1M Tris-HCl pH 6.8 
1g               SDS 
0.33ml        1% Bromophenol Blue 
5ml             Glycerol 
2.5ml          2-Mercaptoethanol 














1.56ml         1M Tris-HCl pH 6.8 
5ml              10% SDS 
0.175µl        2-Mercaptoethanol 
Make up to final volume of 25ml using Deionised Water. 
 
Lysis Buffer 
50mM          HEPES pH 7.5 (SIGMA-ALDRICH) 
1%               NP-40 
10%             Glycerol 
50mM          NaCl 
10mM  NaF 
1 tablet        Complete Mini Protease Inhibitor Cocktail (Roche) 
1 tablet        Phos Stop Phosphatase Inhibitor Cocktail (Roche) 
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